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Androgen deprivation therapy (ADT) can increase survival from prostate cancer by up to 2-3 
years, but tumours invariably relapse into an ADT-unresponsive, incurable form, known as 
castrate resistant prostate cancer (CRPC). CRPC is more aggressive and more likely to 
metastasise to bone, worsening morbidity and mortality. Mesenchymal stem cells have 
been implicated in alteration of androgen signalling within prostate cancer cells and 
stimulation of metastasis and resistance to anti-tumour therapy, and thus may play an 
important role in the development of castration resistance. A high throughput screen to 
identify compounds that inhibit the effect of MSCs on castration resistance would thus be 
valuable in development of novel chemotherapeutics against CRPC.  
Clones of the human CWR22PC and murine Myc-CaP Bo prostate cancer cell lines were 
characterised by their reduced growth in response to androgen deprivation, modelled using 
charcoal stripped serum and the antiandrogen enzalutamide. Investigations were 
performed to optimise the miniaturisation of this assay. The effect of conditioned media 
from human or murine mesenchymal stem cells on this cell growth was then examined in 
the presence of androgen and androgen deprivation, in a high-throughput format.  
It was found that MSC-conditioned media had only a small positive effect stimulating 
growth in CWR22PC cells, greatest in the enzalutamide-treated condition. In the murine 
Myc-CaP Bo cell line clone 5GSH-6943#5, MSC-conditioned media significantly stimulated 
castration-resistant growth in the androgen deprivation condition but not in the presence 
of androgen. However, assay validation indicated that the assay developed for either cell 
line was not suitable for high-throughput drug screening in its current form. Further 
optimisation is thus required for use of the assays developed as a platform for high-
throughput screening to investigate the effects of various therapeutic compounds on MSC 









Prostate cancer is the most common cancer in males and amongst all cancers is the second 
greatest killer of men. The growth of prostate cancer at first requires the hormone 
testosterone; most successful treatments against the cancer have relied upon greatly 
reducing the amount of testosterone in the body by physical or chemical castration, or 
preventing testosterone that is present from stimulating cancer cells: this is known as 
androgen deprivation therapy (ADT). These treatments are effective at controlling prostate 
cancer for up to 2 or 3 years, but eventually stop working. After this happens, the cancer 
once again grows quickly and aggressively and is more likely to spread to the bones, 
increasing the risk of both death and complications such as bone fractures and pain, which 
often significantly harm quality of life.  
The reasons for this appear to involve changes in the way cells of the prostate cancer 
respond to testosterone. These changes may be brought about with the help of other, non-
cancerous cells associated with the tumour, in particular a type of bone marrow stem cell 
known as a mesenchymal stem cell (MSC). This study involves the design of a method of 
investigating the effect MSCs may have on prostate cancer cells and their sensitivity to 
testosterone withdrawal. 
It was found that secreted factors from MSCs stimulated growth of human and mouse 
prostate cancer cells, and that this effect was greatest when cells were deprived of 
testosterone. This experiment may form the basis of a drug screening program to 
investigate many different chemical compounds for their potential to improve the effects of 
ADT, and reduce the stimulation of prostate cancer cell growth by MSCs during androgen 
deprivation therapy. Such a study would be a step forward in improving and lengthening 
the lives of men with prostate cancer. However, the experimental methods developed in 
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Chapter 1 | Introduction 
 
1.1.1 | Castration resistant prostate cancer 
In men, prostate cancer is the most common type overall and the second most common 
cause of cancer death, accounting for 28% of new cancer cases and 10% of deaths from 
cancer in men in the US: over the course of his lifetime a man has a one in six probability of 
developing invasive prostate cancer 1. In the UK, there were 46,700 new cases of prostate 
cancer in 2014, of which roughly 4 in 10 were diagnosed at a late stage, and 11,300 deaths 
2. This disease thus poses a large burden on male quality of life and on health services. 
When it arises, prostate cancer (PCa) growth is dependent on androgen, and therefore first 
line treatment for metastatic prostate cancer is androgen deprivation therapy (ADT). 
Androgen deprivation therapy induces remission of the tumour for 2-3 years 3, however, 
invariably the tumour develops resistance to ADT and relapses as castration resistant 
prostate cancer (CRPC). After relapse, tumours are particularly aggressive, with mean 
survival time only 16-18 months 3. Medical advances have caused significant improvements 
in prostate cancer death rates: 10 year-survival in the UK is 84%, compared to around a 
quarter in the 1970s. A significant amount of this decline in mortality is due to PSA 
screening allowing earlier detection 2. 
Castration resistant prostate cancer is particularly associated with bone metastasis, present 
in over 90% cases, most commonly in the spine 4. In addition, highly metastatic prostate 
cancer is more likely to become castration-resistant 5,6. There is evidence of a link between 
a highly invasive prostate cancer phenotype and castration resistance: for example, Shiota 
et al (2015) found that more highly invasive CWR22Rv1 clones showed higher AR 
expression and growth rate in the absence of androgen 6. Bony metastases have a 
profoundly negative effect on prognosis in terms of both mortality and morbidity, with 
osteoblastic bone metastases causing complications such as pain, spinal cord compression, 
pathologic fractures and hypercalcaemia, with a significant negative effect on quality of life. 
Androgen deprivation therapy itself is also associated with osteoporosis and increased risk 




1.1.2 | Androgen deprivation therapy and treatment of prostate cancer 
The discovery of androgen deprivation as a treatment for prostate cancer was made by 
Charles Huggins et al in 1941, who found that orchidectomy or administration of oestrogen 
induced tumour regression in all cases but one, and reduced pain from bony metastases 10. 
Orchidectomy was later superseded in many cases by LHRH and GnRH analogues, which 
provided equivalent increases in survival, but were of course much less invasive 11,12. These 
analogues caused an initial sharp increase in testosterone production followed by feedback 
inhibition of secretion: the negative effects of this ‘testosterone flare’ led to development 
of LHRH and GnRH antagonists, which act to inhibit testosterone secretion without the 
initial flare 13. Later, agents acting to block the androgen receptor directly were introduced, 
such as cyproterone. These first-generation antiandrogens were followed by non-steroidal 
antiandrogens, such as flutamide and bicalutamide, which lacked central and 
progestational side effects of their forebears, including impotence and reduced libido 11. 
However, these drugs have several-fold lower affinity for the AR than androgens and their 
function is vulnerable to AR mutations in the ligand binding domain (LBD) causing them to 
act as partial agonists, reducing the effectiveness of AR inhibition 11,14.  
The shortcomings of these drugs led to the development of 2nd generation antiandrogens 
such as enzalutamide (MDV3100, brand name Xtandi). Enzalutamide does not only block 
testosterone binding to the AR but also inhibits nuclear translocation, recruitment of 
cofactors and binding to DNA 15. This would mostly prevent partial agonist effects 16, 
although AR mutations have been identified which confer agonism of enzalutamide 17. 
Enzalutamide has been found to be have substantially higher antitumour activity compared 
to bicalutamide in mouse xenograft models 15. In patients, enzalutamide improves survival 
in metastatic CRPC that does not respond to other forms of ADT: in the AFFIRM phase 3 
trial, it was found to decrease risk of death by 37% compared to a placebo in patients with 
metastatic CRPC previously treated with docetaxel, and outperformed the placebo at all 
secondary end points 18. The benefit of enzalutamide in CRPC supports the idea that AR 
signalling may be still required for growth and maintenance of the tumour, even under 
castrate levels of testosterone 19.  
Only 8% of prostate cancer patients in the UK are treated by major surgical resection of the 
tumour, with resection more likely in younger patients and not recommended for patients 
aged above 75 20. Prostate cancer tends to be less aggressive in older patients: due to low 
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mortality, therefore, resection of the tumour in these patients often does more harm than 
good 20. However, the morbidity of metastasis highlights the importance of treatment. Risk 
of metastatic progression may be assessed by PSA level: low risk localised disease is 
generally managed by active surveillance, including periodic PSA testing, digital 
examination, prostate biopsies and MRI scanning. High risk localised prostate cancer may 
be treated with radical prostatectomy or radiotherapy; pelvic radiotherapy is also used in 
locally advanced disease, and may be combined with high-dose rate brachytherapy or 
androgen deprivation therapy in intermediate and high risk localised disease 9. When given 
alone for early stage prostate cancer, ADT does not appear to give any survival benefit and 
may actually worsen survival 5,21. 
Long term ADT, which may be administered intermittently, is used to treat locally advanced 
and metastatic prostate cancer. LHRH agonists such as goserelin or buserelin are the main 
form of ADT prescribed in the UK; the antiandrogen cyproterone acetate may also be given 
prophylactically against testosterone flare 22. The GnRH antagonist degarelix is 
recommended for hormone sensitive PCa which has metastasised to bone 23. Bilateral 
orchidectomy is also offered to all men, but anti-androgen therapy is not used first-line in 
metastatic PCa. Castration resistant prostate cancer is treated first line by docetaxel and 
corticosteroid therapy 22, with antiandrogens often administered after the failure of first 
line treatments 7: in the UK, enzalutamide is given to men with prostate cancer refractory 
to docetaxel and other forms of ADT 24. Notably, enzalutamide and bicalutamide have been 
reported to stimulate invasion of prostate cancer cells by promoting macrophage migration 
to them, to enhance CCL2 signalling and to increase the number of distant metastases in 
the diaphragm and lymph nodes 25. 
 
1.1.3 | Dysregulation of androgen receptor signalling is associated with progression to 
CRPC 
The androgen receptor (AR) is an intracellular steroid hormone receptor activated by the 
ligands testosterone and dihydrotestosterone (DHT). In the prostate, testosterone, 
produced mainly in the testes, is reduced to DHT, which is a more potent agonist of the AR, 
with an EC50 of 0.13 compared to 0.66 for testosterone 26,27. The AR consists of three 
functional domains: the N-terminal regulatory domain, the ligand-binding domain (LBD), 
and the DNA binding domain. Upon androgen binding, the receptor-ligand complex 
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undergoes a conformational change, dissociates from heat-shock proteins, and translocates 
to the nucleus, where it dimerises and with an array of coactivator and corepressor 
molecules modulates expression of many androgen-responsive genes, for example PSA, by 
action on androgen-response elements (AREs) 11,27.  
The fact that AR expression usually persists even in castrate resistant cancer 28, and that 
enzalutamide continues to have efficacy in metastatic CRPC resistant to other 
antiandrogens 18, strongly suggests that CRPC growth remains dependent on AR signalling, 
even when testosterone is reduced to castrate levels. Multiple mechanisms involving 
androgen signalling have been proposed to explain progression to CRPC: some of these are 
summarised in Figure 1. Firstly, mutations in the AR ligand binding domain can allow for 
stimulation by non-androgenic ligands 16. For example, the T877A point mutation in AR, 
when selectively mutated in mouse prostate epithelium, caused prostate hypertrophy and 
growth stimulation by oestrogen and the AR antagonist bicalutamide. Whilst this mutation 
did not induce prostate cancer formation alone, it accelerated tumorigenesis in the TRAMP 
mouse model of prostate cancer, and after castration there was less reduction in tumour 
growth in mutated compared to control mice 29. In addition, cells of the androgen-sensitive 
cell line CWR22PC and the castration resistant CWR22Rv1 line both express the H874Y 
mutation in the AR LBD, as do CWR22 tumours from which these cell lines are derived. This 
mutation has been shown to increase the agonist response of the AR to DHEA, estradiol, 
progesterone and hydroxyflutamide several-fold 30. Castration-sensitive CWR22PC cells 
possess this mutation, but lack an exon 3 duplication present in CWR22Rv1 cells and 
relapsed, androgen-insensitive CWR22 tumours 31: AR with this duplication has been shown 
to exhibit constitutive nuclear localisation and DNA binding 32. Whilst enzalutamide was 
developed partially to avoid the agonist effects of other antiandrogens, other mutations in 
the AR have been shown to rescue the growth inhibition caused by enzalutamide and cause 
the drug to act as an agonist at the AR 17. Notably, AR pathway mutations are present in 
71.3% of metastatic CRPC cases, and are exclusive to CRPC over primary prostate cancer 33.  
Secondly, downstream AR signalling pathways may be activated by alternative mechanisms 
without ligand binding to the AR. Significant crosstalk exists between the AR and growth 
factor signalling pathways 34: alternative signalling events, (for example, PTEN loss) may 
bypass the need for androgen signalling entirely 16,27,35. Receptor tyrosine kinases (including 
EGFR, IGF-1R and IL-6R), may also activate AR without androgen binding: in particular, the 
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HER2 receptor, acting through downstream kinases such as Ack2, increases AR activity and 
becomes overexpressed as prostate cancer progresses to CRPC 36. 
Notably, Chen et al. (2004) found that PCa tumours expressed higher levels of AR after 
passage through castrated mice to induce castration resistance; and that introduction of 
additional AR cDNA to cells conferred a greater growth rate in charcoal stripped serum 
(CSS) and more tumour formation in castrated animals. Castration resistant growth still 
required ligand binding, but AR upregulation allowed functional androgen signalling at 
castrate testosterone concentrations. It appears this change may involve both AR 
overexpression and changes to levels of cofactor molecules at AR-responsive genes 16. 
These findings are supported by other studies reporting average 6-fold higher AR 
expression in CRPC samples compared to benign hyperplasias 37. In addition, around 30% of 
hormone refractory tumours possess gene amplification of the AR, which is not present in 
androgen dependent PCa, although AR was still significantly upregulated in refractory 
tumours lacking the amplification: there are thus multiple methods of AR overexpression 
37,38. Notably, mutations in codon 877 were not seen in tumours with AR amplification 38, 
demonstrating that multiple discrete possible genetic alterations to the AR can give rise to 
CRPC.  
However, these findings appear to be partially contradicted by RNA microarray data from 
radical prostatectomy samples, showing that whilst elevated AR expression was associated 
with higher growth rate and reduced survival time before tumour recurrence, AR 
expression was in fact lower in castration-resistant metastases 39,40. The authors of this 
study suggest that AR signalling may still be enhanced in metastases by mutation in AR 
allowing activation by noncanonical ligands (as previously described 16,41), or that 
immunochemistry may not be able to detect increased amounts of mutated AR 39. It was 
also found that AR levels tended to be higher in bone metastases, and that increased AR 
expression was associated with reduced recurrence-free survival 39. In addition, expression 
of the stem cell-associated protein nestin has been shown by Kleeberger et al. (2007) to be 
required for metastasis of AT6.3 prostate cancer xenografts, and appears to be dependent 
on castration resistance. This study found that nestin expression was detectable only in 
lethal castration-resistant disease and androgen independent PCa cell lines, and 
undetectable in ADT-naïve tumours, even in metastases 42. It thus appears that the role of 
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androgen signalling in acquisition of castration resistance is not limited to a single 
mechanism.  
 
1.1.4 | AR signalling and ADT have different effects on different cell types in prostate 
cancer 
The effects of androgen signalling in prostate cancer are not limited to tumour cells alone, 
however. Niu et al (2008) have described how AR signalling in stromal cells promotes PCa 
progression and invasion, whilst in prostate epithelial cells acts to suppress invasiveness 40. 
Effects of androgen also vary between different prostate cell types: prostate epithelial AR 
signalling was found to suppress proliferation of basal prostate cells (which are mostly AR 
negative) and promote survival of AR+ luminal cells 40. In normal homeostasis, AR signalling 
is required for differentiation of basal cells into luminal cells and maintenance of luminal 
cell morphology 43. Epithelial AR knockout in a murine prostate cancer model leads to 
expansion of the more highly tumourigenic and metastatic basal and intermediate cells, 
Figure 1: AR signalling and mechanisms of castration resistant AR signalling. The intracellular AR is 
activated by testosterone or DHT binding, whereupon it translocates to the nucleus and modulates 
transcription at androgen response elements (AREs). Antiandrogens block this, however AR transcriptional 
activity may also be activated by tyrosine kinases (“non-genomic” activation) or by overamplified or mutant 
AR. Adapted from Chen et al (2008) 36.  
21 
 
leading to less differentiated, larger tumours 44. This is consistent with data showing that 
ADT and antiandrogens may stimulate prostate cancer progression and metastasis 25. 
Contradicting this study, Xie et al (2017) found that although AR knockout in luminal cells 
caused a burst of proliferation and with cells gaining a more intermediate phenotype, this 
burst was transient and the cells did not form tumours 43.  
When stromal and epithelial AR were knocked out simultaneously at 16 weeks, however, 
smaller, less differentiated tumours with a lower proliferation and greater apoptosis rate 
developed: metastasis was suppressed and survival time increased 44. The effects of ADT on 
prostate cancer therefore appear to depend on the balance of androgen signalling between 
different cell types. In the early stages of tumour growth, protumourigenic stromal AR 
signalling predominates, thus ADT effectively inhibits tumour growth. However, at later 
stages, alterations to AR signalling and the tumour stroma may cause the expansion of 
basal and intermediate cells to become the dominant effect, stimulating tumour growth 
and metastasis 44. In support of this, a model of enzalutamide-resistant CRPC with 
combined TP53 and RB1 knockdown showed an increase in basal and neuroendocrine and a 
decrease in luminal cell markers 45.  
 
1.1.5 | Cells of the tumour stroma form a microenvironmental niche to support 
tumorigenesis 
The role of stromal AR signalling discussed above is only one facet of the vital role played by 
stromal cells in tumour progression. For example, cancer associated fibroblasts (CAFs) are 
descendent cells of MSCs which modify the extracellular matrix by production of matrix 
metalloproteinases (MMPs) to facilitate invasion and metastasis, and recruit a variety of 
other cell types such as leukocytes and endothelial cells to the tumour environment 46. 
These recruited cells may themselves aid tumour progression: for example, M2 
macrophages promote tumour growth 47 produce ROS which may cause tumorigenic 
mutations 48. Pericytes transitioning into cancer associated fibroblasts have also been 
implicated in facilitation of invasion and metastasis in fibrosarcomas 49,  whilst CAFs in 




Signalling crosstalk between stromal cells and with cancer cells forms a tumour niche, 
comprising beneficial paracrine signalling and microenvironmental conditions to facilitate 
tumour growth and progression. This is particularly important to facilitate the 
establishment of new metastases. Stromal cells can form pre-metastatic niches to support 
cancer cell engraftment before tumour cell arrival or around single disseminated mammary 
tumour cells 51,52. In the bone marrow, MSCs and many other stromal cell types maintain 
the haematopoietic stem cell (HSC) population, but PCa cells usurp this HSC niche to 
support metastatic growth, forming the bone metastatic niche 53. Stimulating HSC 
mobilisation also causes egress of cancer cells, implying the HSC and metastatic niches are 
maintained by similar mechanisms 54. Also, breast cancer cells home preferentially to 
osteoblast-rich areas of bone marrow, suggesting osteoblasts play an important role 55. This 
niche also maintains PCa in a dormant cancer stem cell (CSC) phenotype 56, which may 
confer greater resistance to anticancer therapies 57.  
 
1.1.6 | MSCs home to tumours and stimulate tumour growth 
Notably, osteoblasts and fibroblasts are both cells derived from mesenchymal stem cells 
(MSCs) 58. MSCs are multipotent cells present mainly in the bone marrow and adipose 
tissue, with a wide variety of functions including immunosuppression and tissue repair, and 
have been shown to promote tumour growth and help confer resistance the chemotherapy 
58,59. Under normal circumstances, MSCs are present in the prostate at a low level 60, but are 
recruited to sites of tumorigenesis due to chronic inflammation and have a number of 
effects at the primary site, as summarised in Figure 2. The exact mechanisms behind this 
recruitment are not completely understood, particularly as MSCs are a heterogenous 
population capable of expressing a wide range of cell trafficking surface molecules, but due 
in part to their homing to damaged and inflamed tissues, MSCs are believed to be attracted 
by similar mechanisms to leukocyte recruitment, via chemokines such as CCL5, CXCL2, 
CCL3, CCL2 and CXCL8 61. Expression of these molecules is stimulated by proinflammatory 
molecules such as VEGF and TNFα secreted by the primary tumour: this secretion may be 
stimulated through pathways such as HIF-1α produced in response to hypoxic conditions in 
the tumour 61. CXCR4-SDF1 interaction has been implicated in MSC trafficking 62,63 to 
tumour sites, however, other studies have shown blocking CXCR4 did not affect MSC 
migration to damaged myocardium in vivo 64. 
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Once at the tumour site, MSCs are protumourigenic: for example, co-inoculation of MSCs 
with PC3 prostate cancer cells was shown to increase tumour proliferation, migration and 
invasion through a TGFβ-dependent mechanism 65. IL-6 secretion by MSCs has also been 
shown to promote tumour cell survival, bone turnover and resistance to cytotoxic therapies 
66,67. MSCs also recruit and interact with immune cells in the niche, with broadly 
immunosuppressive effects which may help the tumour escape of the immune response 66; 
in addition, CXCR2-mediated recruitment of neutrophils by MSCs helps stimulate metastasis 
in breast cancer 68, whilst recruitment and of macrophages through CCR2 signalling 
promotes tumour growth 47. Crosstalk between MSCs and tumour cells is important for 
development of the tumour microenvironment 53: TGFβ secreted in exosomes by prostate 
cancer cells has been shown to stimulate differentiation of MSCs towards a myofibroblastic 
phenotype, with higher ability to stimulate tumour growth, invasion, and angiogenesis 69. 
1.1.7 | MSCs stimulate prostate cancer bone metastasis and form part of the bone 
metastatic niche 
MSCs are commonly found in bone marrow 58 and are recruited to the bone marrow niche 
to aid cancer cell metastasis and growth, through mechanisms summarised in Figure 3. 
VEGF secreted by the primary tumour in a breast cancer model has been shown to 
stimulate stromal cell production of prostaglandin E2, which attracts BM-MSCs to aid in 
Figure 2: MSCs migrate to the primary tumour due to tumour cell chemokine production and chronic 
inflammatory signalling. As part of the tumour stroma MSCs stimulate tumour growth, metastasis and other 
hallmarks of cancer by multiple mechanisms, including TGFβ signalling. MSCs are stimulated by reciprocal 




formation of a premetastatic niche 53,70. MSC migration to the niche has also been shown to 
be stimulated by SDF1 – CXCR4 signalling 62. In breast cancer, bone marrow MSCs of the 
niche then attract disseminated cancer cells and facilitate their migration across bone 
marrow endothelium through secretion of SDF1α 63,71. Once in the niche, tumour cells 
modulate MSC and other stromal cell phenotypes to support metastatic growth 53. IL-6 
secretion by MSCs stimulates proliferation and survival of tumour cells, modulation of other 
stromal cells of the bone marrow niche, and a cancer stem cell phenotype associated with 
therapy resistance 53,57. Exosomes from MSCs have been found to induce dormancy and 
docetaxel resistance in metastatic breast cancer cells in the bone marrow 72, and to induce 
resistance to multiple chemotherapeutic drugs in vitro by secretion of platinum-based fatty 
acids 59. This conferred chemoresistance may help PCa cells overcome inhibition by 
antiandrogens, HSCs of the bone marrow niche stimulate osteoblastic differentiation of 
MSCs into osteoblasts 71, which have protumourigenic effects and an important role in the 
bone marrow metastatic niche 53,55.  
1.1.8 | MSCs contribute to prostate cancer castration resistance 
Prostate cancer metastatic ability and castration resistance are closely linked, and 
influenced by the tumour microenvironment both at the primary site and in the bone 
Figure 3: Actions of MSCs at the bone metastatic site. MSCs under normal conditions form part of a HSC 
niche that may be co-opted by tumour cells, susceptibility to tumour cell engraftment may be increased by 
prostaglandin E2 as the tumour cells form a premetastatic niche to which tumour cells migrate through 
SDF-1–CXCR4 signalling. Crosstalk with tumour cells alters the phenotype of MSCs and other stromal cells 
of the niche to aid tumour growth; MSCs perform many functions to stimulate progression of secondary 




metastatic niche. LNCaP prostate cancer cells cultured with prostate or bone stromal cells 
showed both enhanced castration resistant growth and greater metastatic potential, 
particularly to lymph nodes and bone, when transplanted into castrated mice 73. Bone 
marrow MSCs have also been found to stimulate invasive and metastatic potential and self-
renewal ability of prostate cancer cells through a mechanism dependent on suppression of 
androgen signalling by CCL5: notably, this effect did not occur in PC3 cells where AR is 
absent 74. If suppressing androgen signalling stimulates prostate cancer growth and 
metastasis, as is consistent with other studies that have previously been discussed 25,40,44, 
this may be a reason why androgen deprivation eventually fails. 
In addition to stimulating prostate cancer cell growth and metastasis 65, mesenchymal stem 
cell TGFβ signalling has also been shown by Cheng et al (2016) to promote castration 
resistance of LNCaP cells in vivo and in vitro. In this study, MSC co-injection with LNCaP PCa 
cells into castrated nude mice increased the castration-resistant growth of resultant 
tumours. In addition, treatment with MSC-conditioned media almost completely rescued 
the growth and apoptosis rate of LNCaP cells under androgen deprivation in vitro. LNCaPs 
pre-treated with MSC conditioned media also grew faster than control tumours in castrated 
mice, to roughly the same tumour volume in non-castrated mice. There was also no 
additional effect of MSC conditioned media when androgen was present in vivo or in vitro. 
These results indicate that, at least in LNCaP cells, the effect of MSCs on tumour growth is 
predominantly in stimulating castration resistance, and this effect is due mostly to secreted 
factors.  The increase in castration-resistant growth was ablated by shRNA-mediated 
knockdown of TGFβ in MSCs. Furthermore, it was found that exposure of MSCs to androgen 
inhibited their expression of TGFβ and greatly reduced their stimulation of castrate 
resistant growth in vivo and in vitro 75. In this case, therefore, androgen deprivation therapy 
could cause upregulation of MSC TGFβ secretion and thus stimulation of castration-
resistant tumour growth, leading to failure of ADT and progression to CRPC. Ye et. al. (2012) 
also found that conditioned media from MSCs contained substantial TGFβ, and 
administration of TGFβ-blocking antibody inhibited their stimulation of PC3 migration and 
invasion in vitro 65. MSC TGFβ secretion thus appears to be a link between prostate cancer 
cell metastatic ability and castration resistance. 
Androgen deprivation has also been shown to upregulate both TGFβ1 and TGFβ receptors 
in prostate cancer cells themselves 76. Notably, TGFβ may induce epithelial-mesenchymal 
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transition of prostate cancer cells (stimulating metastasis) and stimulate overexpression of 
the androgen receptor 6, which is associated with castration resistance 16. Once again this 
suggests a link between metastasis and CRPC. Other studies suggest downregulation of AR 
signalling stimulates prostate cancer invasion and growth of the cancer stem cell 
population 74 – whilst an apparent contradiction, as the authors state, AR may act to 
suppress metastasis but promote growth and castration resistance 74, and the overall 
effects of AR signalling may depend upon the stage of tumour progression 44. The 
relationship between metastatic ability and therapy resistance has also been demonstrated 
in other cancers: Yano et al showed that a much higher proportion of invading than non-
invading stomach adenocarcinoma cells were in G0/G1 phase, which was associated with 
increased resistance to cytotoxic therapy 77. However, human MSCs have been shown to 
increase the proportion of actively dividing PC-3 prostate cancer cells whilst still stimulating 
cell division 65. 
TGFβ may also act to increase the size of the CSC population and confer resistance to 
paclitaxel in breast cancer 78. However, in contradiction of these reports suggesting a role of 
TGFβ signalling in progression to CRPC, Placencio et al have shown that TGFBR2 knockout in 
stromal cells induces castration resistance, and that TGFβ acts to maintain androgen 
sensitivity and enable prostate regression by suppression of Wnt signalling 79. Notably, 
castration resistant CWR22Rv1 prostate cancer cells express abnormally low levels of the 
TGFβ type II receptor 80, and androgen deprivation has been shown to reduce prostate 
cancer cell TGFBR2 expression 76. TGFβ1 overproduction and TGFBR2 loss are also 
associated with poor clinical outcome, however 81. The effects of TGFβ on androgen 
sensitivity are thus complex may thus depend on the balance of receptor expression on 
prostate cancer cells.  
In a follow-up study, Placencio et. al. found that bone marrow derived MSCs are recruited 
to and incorporate into the prostatic epithelia in response to androgen deprivation, likely 
through the CCL5-CCR5 axis, and stimulate castration resistant growth through paracrine 
Wnt signalling 82. Wnt proteins have also been found to be secreted by metastatic prostate 
cancer cells in the bone marrow, stimulating MSC differentiation into osteoblasts and 
stimulating formation of osteoblastic bone lesions 83. Aberrations in Wnt signalling have 
been found to be present in 18% of mCRPC cases 33, suggesting a role for these pathways in 
progression to castration resistance. 
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1.2.1 | Aims and objectives 
MSCs are thus implicated through multiple mechanisms in PCa acquisition of castration 
resistance, both at the primary tumour and the metastatic site. This, and the association 
between castration resistance and aggressive, bone-metastatic cancers speak to the 
importance the role MSCs may play in prostate cancer morbidity: inhibiting their effects has 
potential to greatly improve the lives of prostate cancer patients. The aim of this project 
was thus to develop a high-throughput assay showing the effects of MSC stimulation on 
prostate cancer cells both with and without androgen deprivation. This assay could then 
form the basis of a high throughput screen (HTS) to identify compounds from a drug library 
which inhibit these effects. Identification of said compounds would help elucidate 
mechanisms by which MSCs affect prostate cancer response to ADT, and could be further 
investigated and developed to identify lead compounds for development of new drugs to 
prolong survival and reduce morbidity from CRPC.  
 
1.2.2 | The present study 
The CWR22PC cell line was used as a model of androgen-responsive human prostate 
cancer. This cell line is derived from highly androgen-sensitive CWR22 prostate tumours, 
which go into remission upon androgen deprivation for 7-9 months followed by relapse as 
castration resistant tumours 31,84. CWR22 xenograft tumours in mice have a much greater 
response to castration than LNCaP or PC-346 tumours, regressing to a much greater degree 
and for a longer period before relapse 85. In addition, CWR22PC cell growth is more reliant 
on androgen than LNCaP cells both in vitro and in vivo 31. CWR22PC cells also possess the 
H874Y mutation which allows non-androgenic ligands to stimulate the AR 30, a possible 
mechanism by which progression to CRPC may occur in this cell line. These cells therefore 
provide a representative model of prostate cancer cells in human tumours before 
progression to CRPC. 
This study also investigated these phenomena in the Myc-CaP murine prostate cancer cell 
line, isolated from a c-Myc driven transgenic mouse prostate cancer model 86. These cells 
have greatly amplified AR but remain androgen-dependent both in vitro and in vivo, and 
following androgen deprivation in vivo Myc-CaP tumours progress to CRPC. AR 
amplification is seen 30% of CRPC cases 37,38 and thus this cell line appears to be 
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representative of progression of cells towards castration resistance. In these cells androgen 
signalling stimulates growth by maintaining expression of the oncogene c-Myc: in Myc-CaP 
sublines that had become castrate-resistant, c-Myc expression under androgen deprivation 
was equal or raised compared to androgen-dependent clones, suggesting upregulation of 
androgen signalling despite castrate levels of androgen 86. The ability of these cells to 
transition from hormone-sensitive to refractory suggests they are a good model for 
investigation of progression to CRPC. These experiments used 5GSH-6943#5 cells, a mixed 
clone derived from Myc-CaP cells passaged through mice to select cells for cells with 
propensity to metastasise to bone (unpublished data).  
To investigate the response of 5GSH-6943#5 cells to MSC conditioned media, the 
C3H10T1/2 murine MSC line was used. C3H10T1/2 cells were established from C3H mouse 
embryos 87, and have been shown to have similar immunosuppressive properties and 
express similar receptors for immune cell recruitment as primary murine MSCs 88,89, and to 
promote tumour growth in vivo 88. C3H10T1/2 cells appear to be a good model of bone 
marrow-derived MSCs, with similar osteogenic and chondrogenic ability, although they are 
less able to undergo adipogenesis than mouse primary BM-MSCs 90. As prostate cancer 
forms osteoblastic lesions, it appears that a cell line with similar osteogenic potential would 
be a good model. However, whilst in vivo and primary BM-MSCs are heterogenous, with 
different phenotypes and differentiation potentials, the C3H10T1/2 cell line is homogenous 
90, and thus fully recapitulate MSC functioning in in vivo pathophysiology.  
These cells were used in cell viability assays, seeding cells into 24- or 96- well plates and 
treating with charcoal stripped serum (CSS), enzalutamide (MDV3100), dihydrotestosterone 
(DHT) and MSC- conditioned media. Charcoal-stripping serum removes non-polar 
molecules, including androgens, and therefore acts as androgen deprivation. Cell growth 
over the assay period was measured either by confluence through analysis of microscope 
images, or by the cell viability assays MTT and CellTiter-Blue. MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) is a yellow tetrazolium salt which is reduced by 
viable cells to formazan, an insoluble dark blue product which can be quantified by 
absorbance 91. This reaction occurs intracellularly, catalysed by dehydrogenases on 
mitochondrial cytochromes B and C 92. CellTiter-Blue is an assay that functions in a similar 
manner, in this case by reduction of the blue, nonfluorescent due resazurin to the pink, 
fluorescent product resorufin. Unlike MTT, which kills the cells, CellTiter-Blue is relatively 
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non-toxic; furthermore, resorufin is excreted into the media from the cells, and thus can be 
read by fluorescence directly from the plate without further processing 93. Whilst it is 
commonly assumed that the reading obtained is directly proportional to cell number, in 
both assays more metabolically active cells will produce a greater signal.  
Initial assays were performed at low throughput in 24 well plates to a previously 
established lab protocol, and were then miniaturised onto 96 well plates to form the basis 
of a high-throughput screen. The process of miniaturisation required optimisation to the 
higher throughput platform, as in order able to identify such compounds, a high assay 
quality is required, as indicated by a measure such as Z-factor 94. For optimisation of the 
time course and starting cell density of the assay, an IncuCyte Zoom live cell imaging system 
was used to capture kinetic data of cellular confluence by periodic imaging over multiple 
days.  Once the assay was optimised and used to demonstrate the response of the cells to 
ADT and MSCs, assay validation via min-max signal variability assays was performed to 
establish suitability for high throughput screening 95.  
 
1.2.3 | High throughput screening 
 High throughput screening (HTS) compares the effects of many thousands of drugs or other 
chemicals from a compound library against assay controls. ‘Hit’ compounds with a 
detectable positive effect can then be further analysed by dose response and process 
validation 96.  Such a screen would aim to identify compounds which could increase 
susceptibility of cells to androgen deprivation and inhibit the protective effect of MSCs. HTS 
has become one of the primary methods of drug discovery by the pharmaceutical industry 
97, and is used both to identify novel lead compounds without identification of a target 
molecule (a primary screen), or to test and validate compounds identified by other more 
targeted strategies such as high throughput biological assays (detecting, for example, the 
concentration of a molecule produced), or investigations based on the structure of 
receptors or other target molecules. When used as primary screens, analysis of hit 
compounds may also reveal information about the mechanisms involved in the 
phenomenon in question. This information may aid in a more targeted approach to drug 
discovery, investigating compounds affecting these mechanisms: this may involve further 
high throughput screening using a more targeted drug library. HTS provides the ability to 
perform many assays in a short time period, allowing testing of many combinations of 
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compounds to detect synergistic effects: for example, screening using the assay designed in 
this study in human cells would test the effects of both the candidate compound and 
enzalutamide applied to the cells simultaneously 96.  
HTS is frequently used in complementary fashion with other methods of drug discovery: in 
this way, HTS raises efficiency by allowing very high numbers of experiments to be 
conducted. Furthermore, automation and biological assay formats used allow for higher 
levels of precision and sensitivity, and more systemic and unbiased studies. Technology 
developed for HTS has also led to benefits in other areas of drug discovery, such as lead 
optimisation 96, whilst processes and techniques have been adapted and expanded to 
further investigate candidate cancer drugs. High content phenotypic screening may be used 
to identify compounds causing particular phenotypic changes: for example, candidate 
angiogenesis inhibitors may be identified by quantifying their effects on endothelial cell 
tubules using automated imaging systems and specialised analysis algorithms 98. Such 
screens can detect changes in multiple modalities simultaneously, and through 
multiparametric analysis aggregate data to gain detailed information into cellular 
phenotypic responses. Analysis of this data can then elucidate differences in responses 
between different cell lines for the same drug or between different drugs. This can provide 
valuable information regarding drug mechanism of action: for example, by identifying 
compounds with a similar phenotypic response to a drug with a well understood 
mechanism 99. 
However, the success of HTS in the development of new drugs depends on the 
physiological relevance of the assay: if it does not represent the true disease situation in 
vivo, then lead compounds identified by HTS are unlikely to have efficacy in the patient. In 
addition, due to the high number of compounds tested, signal-to-noise ratio must be very 
low and reproducibility very high to successfully identify hits and avoid false positives. 
Thirdly, success requires use of an appropriate drug library: particularly in the early years of 
HTS, libraries were often of limited diversity and contained many compounds, such as dyes, 
which were very unlikely to produce any effect96. HTS is costly, and thus a balance is 
required between sufficient throughput and size of library, and acceptable cost. 
In this project, the androgen sensitivity of prostate cancer cells was characterised using an 
existing low-throughput protocol. This assay was then adapted onto a higher-throughput 
format, and various investigations were conducted to optimise the new protocol. The effect 
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of mesenchymal stem cell conditioned media on cell growth and the interaction of this with 
ADT was then investigated using the high throughput assay. Validation experiments for 
both human and murine cell assays were then performed to establish the suitability of the 
assay as a high throughput screening platform: a successful assay would become a starting 
point for a drug screen to investigate compounds that may inhibit MSC stimulation of 







Chapter 2 | Materials and Methods 
 
2.1 | Cell culture 
All cell lines were cultured in 75 cm2 flasks, changing media every 3 or 4 days. Cells were 
passaged when approaching full confluence using 0.05% trypsin-EDTA (Gibco), with the cell 
suspension centrifuged at 200 x g for five minutes and the resulting pellet resuspended in 
new media before reseeding in a new flask.  
CWR22PC cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (+ 4.5 g/L D-
glucose, 2 mM L-glutamine and 1 mM sodium pyruvate) with 10% heat inactivated fetal 
bovine serum (FBS), 1% Penicillin-Streptomycin (PS) (all purchased from Gibco) and 0.1 nM 
dihydrotestosterone (DHT) (Sigma-Aldrich). Media was changed completely every 3-4 days. 
Individual CWR22PC clones used were supplied by Galadrielle Biver after isolation by 
limiting dilution assay. Prophylactic Plasmocin™ at 5 µg/ml was used to protect clones 
before cryopreservation.  
5GHS-6943#5 were cultured in DMEM + 10% FBS + 1% PS + 1 mg/mL G418 (Geneticin, 
ThermoFisher). G418 was included to maintain selection for iRFP+ cells. iRFP expression was 
tested using a CSU-W1 spinning disk confocal microscope (Nikon).  
C3H10T1/2 cells were cultured in Basal Medium Eagle (BME) (Gibco) + 10% FBS + 1 mM 
sodium pyruvate + 2 mM L-glutamine + 1% PS. Cells were used between the 5th and 15th 
passages only, as per ATCC guidelines. 
Primary human MSCs were cultured in DMEM + 10% FBS + 1% PS, changing media every 3-4 
days. Effort was made to ensure the pH of the media was not too high and that cells were 
not removed from the incubator any longer than necessary. 
 
2.2 | Mycoplasma testing 
Cells were cultured in antibiotic free media for at least 48 hours to a level near full 
confluence before removal of media (1mL) from the flask. This media was then taken and 
centrifuged three times at 13500 x g for five minutes each, resuspending in 1 mL PBS each 
time, before obtaining DNA from the medium via digestion using the Quick Ear Clip 
method. DNA was then amplified by PCR in a reaction mixture containing 1.25 mM Myc 
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detection primers, (as described by Uphoff and Drexler (2004) 100), 2X Biomix Red (Bioline), 
and nuclease-free water (Ambion) in an Applied Biosciences 96 well Thermal Cycler. PCR 
product was then run on a 2% agarose gel, with a band at 510 base pairs indicating a 
positive sample. 
For testing the new stock 5GSH-6943#5 cells, growth media was collected from cells as 
before and centrifuged at 200 x g for 5 minutes to remove cells. The supernatant was then 
tested for mycoplasma with the MycoAlert™ Mycoplasma detection kit (Lonza) by Dr Forbes 
Howie.  
5GSH-6943#5 and C3H10T1/2 cells tested positive for mycoplasma and were treated for 
two to three weeks with Plasmocin™ (InvivoGen) at 25 µg/ml, administered each time cells 
were passaged (approximately every 3 days)  
 
2.3 | Viability assays 
Total viability of cells in each well was measured by either MTT (Sigma-Aldrich) or CellTiter-
Blue (Promega) assays after either three or five days. For the MTT assay, 5 mg/mL stock 
MTT in PBS was added to a final concentration of 250 µg/mL. In 24-well plate experiments, 
this was achieved by direct addition of the stock MTT solution to the growth media (40 µL 
into 800 µL media), whilst in 96-well experiments, MTT solution was first diluted 1:20 into 
DMEM + 10% FBS + 1% PS, before aspiration of media from the wells and replacement with 
100 µL solution containing MTT. Plates were then incubated for 1 hour at 37oC 5% CO2 in 
darkness, before removal of media and washing with PBS. DMSO was added and the plate 
shaken to dissolve formazan crystals; absorbance was then read from the samples in a 96-
well plate at 540 nm using a LabSystems Multiskan EX microplate reader. Three wells 
containing the same volume of DMSO only were read to give a background reading which 
was then subtracted from the OD values for each well.  
For the CellTiter-Blue resazurin reduction assay, CellTiter-Blue was diluted 1:10 into DMEM 
+ 10% FBS and mixed, then media removed from wells of the plate and replaced with the 
media containing the assay reagent. Plates were then incubated for 3 hours in the dark at 
37oC, 5% CO2, before fluorescence was read directly from the plate using a Cytation 3 cell 
imaging multi-mode plate reader (Biotek, courtesy of the Optima CDT programme) at 
585nm, using an emission wavelength of 550nm and gain set at 50. As with the MTT assay, 
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the background signal from three control wells containing 100 µL DMEM + 10% FBS + 10% 
CellTiter-Blue was subtracted from each reading.  
 
2.4 | Measurement of confluence 
96 well plates were imaged using the IncuCyte© Zoom microscope (Essen Bioscience), taking 
four images per well at 10X objective. A sample of these images was taken as an image 
collection, and using IncuCyte© Zoom software, phase contrast, object size filters and hole 
filling were adjusted to maximise accuracy of cell detection. This processing definition was 
then applied to every image, with a confluence of each well found from the mean of the 
confluence values for each of the four images per well.  
 
2.5 | 24-well plate CWR22PC assays testing androgen response 
Cells were trypsinised for 90 seconds with 0.05% trypsin + EDTA (Gibco), then centrifuged 
for 5 minutes at 200 x g, before resuspension and manual counting with trypan blue 
exclusion (Life Technologies) using a FastRead 102 disposable counting chamber (Immune 
Systems Ltd). Cells were then seeded in a 24-well plate at a density of 5000 cells per well. 
The following day, media was aspirated and the wells washed with PBS before application 
of new media containing the treatment conditions, which could contain charcoal-stripped 
serum (Life Technologies), 1 nM 5α-dihydrotestosterone (Sigma-Aldrich) and/ or 1 µM 
enzalutamide (MDV3100), (supplied by the Memorial Sloan Kettering Cancer Centre, New 
York). MDV was stored at 2 mM dissolved in 100% DMSO, and diluted 1:20 to 100 µM in 
serum-free DMEM before adding to the treatment conditions. DMSO diluted 1:20 in serum 
free DMEM was added at the same volume to conditions not containing enzalutamide. 
After a further 3 days media was changed again, using freshly made treatment for the 
conditions containing enzalutamide. 5 days after treatment total viability of each well was 
measured by MTT assay, as described above. 75 µL DMSO was added to each well, and 
after shaking the contents were transferred to a flat-bottomed 96-well optical plate 




2.6 | Seeding density experiments 
Cells were trypsinised using 0.05% Trypsin + EDTA (Gibco), centrifuged at 200xg for 5 
minutes, and counted using a Countess II automated cell counter (ThermoFisher) using 
trypan blue (Life Technolgies) exclusion. Cell suspensions (200 µL) of the two starting 
concentrations were added to column 2 of a 96 well TC-treated flat-bottomed microplate 
(Corning), three replicates of each. PBS (100 µL) was added to the outer wells (column 1, 
12; rows A, H) to prevent evaporation effects, and 100 µL DMEM + 10% FBS +1% PS added 
to other wells. A twofold serial dilution was then performed, transferring 100 µL cell 
suspension into the next column, mixing, and repeating into the next column. A plate map 
of final seeding densities is displayed in Figure 4. The plate was then imaged with an 
IncuCyte® Zoom (Essen Bioscience) microscope at 37oC 5% CO2 for 5 days, taking 4 images 
per well at 10X magnification per well every 1 hour or 3 hours. Images were analysed using 
IncuCyte Zoom® software to yield confluence data. 
2.7 | Dose response experiments 
5GSH-6943#5 cells were seeded at 1500 cells/well in 90 µL, in 96-well plates. After 
overnight incubation, a range of doses from 100 µM to approximately 100 nM of 
enzalutamide were prepared by threefold serial dilution in a round bottomed 96 well plate, 
dissolved in DMEM + 10% FBS + 1% PS + 0.5% DMSO. An additional control well containing 
Figure 4: Plate map of cell seeding density serial dilution. Values indicate number of cells seeded 
per well in 96-well plate, seeded in 100 µL media per well. Outer wells (light blue) filled with 100 µL 
PBS. Seeding densities displayed for CWR22PC and 5GSH-6943#5, but experiments did not 
necessarily include both on a single plate. 
1 2 3 4 5 6 7 8 9 10 11 12
A CWR22PC 5GSH-6943#5
B 12000 6000 3000 1500 750 12000 6000 3000 1500 750
C 12000 6000 3000 1500 750 12000 6000 3000 1500 750
D 12000 6000 3000 1500 750 12000 6000 3000 1500 750
E 8000 4000 2000 1000 500 8000 4000 2000 1000 500
F 8000 4000 2000 1000 500 8000 4000 2000 1000 500




no drug was also included. Enzalutamide-containing media (10 µL) from the serial dilution 
was then applied to the cells to yield a range of concentrations from 10 µM to 
approximately 10 nM across the plate. A plate map showing enzalutamide concentrations 
in the experiment is shown in Figure 5. Three days after initial treatment, all media was 
aspirated and replaced by repeating this process. After a further two days (five days after 
initial treatment), total cell viability in each well was measured by use of the MTT assay, 
using 100 µL DMSO per well and reading directly from the Corning 96-well plate.  
2.8 | Conditioned media experiments 
Human primary bone marrow MSCs in 75 cm2 flasks at minimum 80% confluency were 
washed with 15 mL PBS, and 12 mL new DMEM + 10% FBS + 1% PS then added to the flask. 
After incubation for 24 hours, media was collected and centrifuged at 200 x g for 5 minutes, 
then supernatant passed through a 0.22 µM filter to remove cells, before storage at 4oC. 
Assay conditions were then prepared the same day as conditioned media was collected. 
Conditioned media was diluted by 11/30 in fresh DMEM + 11% FBS or 11% CSS, and 
enzalutamide and DHT added as appropriate to concentrations of 1.1 µM and 1.1 nM 
respectively. DMSO was added as previously described to conditions not containing 
enzalutamide. CWR22PC_GB_22 cells were seeded at 7000 per well and CWR22PC_GB_02 
and 06 clones at 8000 per well in a 96-well plate (Corning) and the outer wells filled with 
100 µL PBS. Two days later, 90 µL of media was aspirated per well and cells then washed 
Figure 5: Plate map of 5GSH-6943#5 dose response experiments. Final concentrations of 
enzalutamide shown: prepared at 10x higher concentration by threefold serial dilution and 10 µL 
added to 90 µL media on the plate. Other wells filled with 100 µL PBS 



























































with 150 µL serum free DMEM, gently with a manual pipette to avoid loss of cells. After 
three days all media was removed from the well and replaced with 100 µL new media made 
up to final concentrations. The same conditioned media used at day 0 was reapplied at day 
3, stored at 4oC in the interim period. Five days after initial treatment, images were taken of 
each well with the IncuCyte Zoom® microscope before performance of either a CellTiterBlue 
(Promega) or MTT (Sigma-Aldrich) assay. 
For testing 5GSH-6943#5 CM response, two 1/15 dilutions of C3H10T1/2 cells were 
cultured for two days, then media removed, cells washed with 10 mL PBS, and 12 mL BME + 
1% sodium pyruvate + 1% L-glutamine + 1% PS with either 10% CSS or 10% FBS was added. 
On the same day, 5GSH-6943#5 cells were seeded in 96-well plates. After 24 hours, 
conditioned media was taken from the flask, centrifuged at 200 x g for 5 minutes and 
filtered at 0.22 µM to remove cells. Assay conditions were prepared the same day: 
conditioned media was diluted 1:2 with DMEM + 10% FBS or 10% CSS before adding 
enzalutamide or DHT to 1 µM or 1 nM respectively; for conditions without conditioned 
media, BME + 1% sodium pyruvate + 1% L-glutamine + 1% PS with either 10% CSS or 10% 
FBS was added to DMEM + either 10% FBS or CSS at a 1:2 ratio. Media was aspirated from 
the plate with a manual multichannel pipette and washed with 200 µL PBS. New media was 
added one column at a time using a single Gilson pipette.  Media was changed using fresh 
conditioned media at day 3 with conditions prepared in the same way. Plates were read for 
confluence data and MTT assay at day 5.  
 
2.9 | Reproducibility/ Min-Max signal experiments 
Cells were seeded in the inner 60 wells of 96-well plates (Corning) at the same density as 
previous 96-well experiments. After one day (5GSH-6943#5 cells) or two days (CWR22PC 
cells), media was changed and, after a PBS wash, the maximum and minimum control 
media added in alternating 6-well columns across the plate, as shown in Figure 6. For 
androgen deprivation min-max experiments, media containing 10% FBS (the maximum 
control) was compared to 10% FBS + 1µM enzalutamide (CWR22PC cells) or to 10% CSS 
(5GSH-6943#5 cells). In conditioned media min-max signal experiments, 10% FBS or CSS 
(the minimum control) was compared to 10% FBS-CM or CSS-CM. Outer wells were filled 
with 100 µL PBS.  Media was changed one column at a time and added using a Gilson single 
pipette to replicate the protocol of the 96-well conditioned media response assay described 
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above. After either 3 days or 5 days, images were taken with an IncuCyte Zoom® microscope 
using the scan-on-demand function, and viability read by either MTT or CellTiterBlue assay. 
For min-max experiments using conditioned media, C3H10T1/2-conditioned media was 
prepared in the same way as described above.  
2.10 | Data analysis 
All statistical analysis was performed using Excel 2016 (Microsoft) and Prism 7 (GraphPad 
Software Inc.). An alpha value of 0.05 was used for all analyses.  
For low throughput CWR22PC androgen sensitivity experiments, raw OD values were 
compiled as grouped data and analysed by paired t-test when comparing two conditions, or 
by two-way analysis of variance (ANOVA), followed by Dunnett’s multiple comparisons test 
when comparing three or more conditions. 
For dose response data, raw OD values for three replicates per concentration tested were 
normalised to the highest mean, and a nonlinear regression performed using Prism 7, 
plotting log (enzalutamide concentration) against normalised OD values, using the variable 
setting. R2 and IC50 values used were those quoted by Prism 7. 
For analysis of CWR22PC_GB_22 response to conditioned media, individual paired t tests 
were performed for each condition with and without CM between the means of three 
technical replicates per experiment: each treatment condition (CSS, CSS + DHT, FBS, FBS + 
Figure 6: Plate map of Min-Max signal experiments. Alternating columns of two control conditions, 
100 µL per well. Outer wells filled with 100 µL PBS. 



























































































MDV) was considered separately. For individual experiments in the CWR22PC_GB_02 and 
GB_06 clones, 2-way ANOVAs were performed, comparing the difference between normal 
and conditioned media for each treatment. Sidak’s multiple comparisons test was then 
performed on these four comparisons. 
For analysis of 5GSH-6943#5 response to conditioned media, the mean OD values at 540nm 
from MTT assays of replicates for the CSS, FBS, CSS-CM and FBS-CM conditions, between 
the 5GSH-6943#5 conditioned media response assay (without media change at day 3) and 
the two min-max assays comparing normal media and CM for each serum, were taken and 
normalised to the mean FBS or CSS value of the three means. A paired t test was then used 
to calculate the p value, grouping data by the individual experiment performed. 
Coefficient of variance (CV) and Z-prime factor (Z’) values were calculated for each min-max 





      







Chapter 3 | Results 
 
3.1 | Human CWR22PC Prostate cancer clones respond to androgen deprivation 
Five CWR22PC clones were tested for their response to androgen deprivation in a 5 day, 
low-throughput 24-well plate assay, quantifying total cell viability by MTT assay. This assay 
was performed three times and the results displayed in Figure 7. Castrate levels of 
androgen, achieved by use of media containing 10% charcoal stripped serum (CSS), caused 
significantly retarded growth compared to fetal bovine serum (FBS) in all clones. In 
addition, all clones except for CWR22PC_GB_02 were found to have significantly lower 
growth after 5 days when treated with 1 µM of the second-generation antiandrogen 
enzalutamide (MDV), although in the CWR22PC_GB_02 clone there was still a strong trend 
towards decreased growth (P=0.0595). All clones showed a greater negative effect in CSS 
compared to 1 µM MDV. 
The MTT assay yielded negative results in at least some wells of experiments with the 
CWR22PC_GB_02, 07, and 12 clones when the absorbance of the DMSO background was 
subtracted. Whilst microscopic inspection revealed that cells stained by MTT were present 
in these wells, it is likely that the signal from these cells was extremely weak due to low cell 
number or viability, and thus was not apparent above natural variation in DMSO 
background readings. Stained cells may have also been inadvertently lost in the washing 
process before addition of DMSO.  
 
3.2 | CWR22PC prostate cancer cell growth is stimulated by exogenous 
dihydrotestosterone (DHT) 
Further investigation of the androgen responsiveness of CWR22PC clones was conducted by 
treatment of cells with 1 nM DHT. For the CWR22PC_GB_,07,12 and 25 clones, total 
viability of cells in a five-day assay was significantly increased by 1 nM DHT in the FBS 
condition, and trended towards a significance in the CWR22PC_GB_02 clone (P=0.0954). 
However, 1 nM additional DHT did not increase growth above FBS in the CWR22PC_GB_22 
clone, suggesting that the amount of androgen present in FBS is already providing maximal 
AR-mediated growth response in this clone (Figure 8A). Notably, the decrease in cell 
viability caused by androgen deprivation was particularly large in this clone (Figure 7), and 
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cells of this clone grew faster than others in culture in FBS (data not shown), supporting this 
possibility. 
All clones showed a very strong trend of increasing growth with DHT administration in the 
CSS condition (Figure 8B). The increase in growth with 1nM DHT is much larger in CSS then 
in FBS, as expected. However, the effect was only statistically significant in the 
CWR22PC_GB_25 clone (P= 0.0044), the GB_07 (P=0.0569) and GB_22 (P=0.0705) clones 
were close to significance. P was equal to 0.1550 and 0.0924 in the GB_02 and GB_12 
clones respectively. The reason why P>0.05 in these clones was likely due to high variation 
in the magnitude of increase between replicate experiments; nevertheless, 1nM DHT 
clearly has a large effect on viability, and further repeats or optimisation to improve assay 
consistency and sensitivity would likely reveal this to be statistically significant. 1 nM DHT 
rescues CWR22PC cell growth in CSS to a similar level to the FBS + DHT condition (data not 
shown), indicating that androgen removal from CSS is responsible for the decrease in cell 
growth: the difference in total cell viability between the CSS and CSS + DHT conditions 
should indicate the maximal effect of AR signalling on the growth of the clone. However, in 
Figure 7: CWR22PC cell growth is inhibited by androgen deprivation. 5-day assay in 24-well plate, changing 
media at day 3. Viability measured by MTT assay, OD 540nm. Data from 3 experiments compared, result from 
single experiment for a given condition represented by a single point, each colour represents a different 
experimental repeat (mean of 3 technical replicates). Bars mean of three repeats (each the mean for one 
experiment) +/- S.E.M. Data normalised to mean FBS value (=1 for each experiment) P < 0.05, comparison with 
FBS + DMSO (One-way ANOVA, Dunnett’s multiple comparisons test) 
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the CWR22PC_GB_07,12 and 22 clones, total viability was lower in CSS supplemented with 
DHT compared to FBS supplemented with DHT (data not shown), suggesting the reduced 
growth in CSS is due in part to loss of other factors. As 1nM DHT should be a saturating 
dose, and this is seen in the CWR22PC_GB_22 clone which did not respond to additional 
DHT in FBS, this effect is unlikely to be due to additional androgen in FBS. There appears to 
be little difference between the FBS + DHT and CSS + DHT conditions in the 
CWR22PC_GB_02 and 25 clones, however. 
  
Figure 8: CWR22PC cell growth is stimulated by androgen administration. 5-day assay in 24-well plate, 
changing media at day 3. Viability measured by MTT assay, OD 540nm. (A) Difference between FBS and FBS 
+ 1nM DHT; (B) Difference between CSS and CSS + DHT. Data mean of 3 replicates from 3 repeat 
experiments, result from single experiment for a given condition represented by a single point, each repeat 
experiment represented by a different colour. Bars mean of three repeats values =/- S.E.M. Data normalised 
to mean FBS (A) or CSS (B) value between 3 experiments (=1 for each experiment). P < 0.05, comparison 




3.3 | Effects of co-administration of DHT and enzalutamide differ between CWR22PC 
clones 
1 nM DHT and 1 µM enzalutamide were added to cells together to study the effects of AR 
inhibition on cells stimulated by maximal androgen signalling. As shown in Figure 9, growth 
rate when both were added was significantly higher than the FBS + MDV condition in the 
CWR22PC_GB_07 and 22 clones, and trended higher in the CWR22PC_GB_12 clone 
(P=0.0738); in the CWR22PC_GB_07 and 12 clones FBS + 1 nM DHT + 1 µM MDV also 
produced a trend of higher growth than FBS alone (P=0.0823 and P=0.1981 respectively), 
despite the presence of an AR inhibitor. A possible explanation for this is that AR block ade 
may cause upregulation of the AR allowing response to additional androgen, or that the 
high concentration of androgen displaced the drug from the AR: enzalutamide has two- to 
three-fold lower affinity for the AR than DHT 39. In this case, additional DHT may displace 
enough MDV to stimulate AR substantially more than the androgen in FBS alone. However, 
there was no significant increase in cell growth compared to FBS + MDV in the 
CWR22PC_GB_02 and 25 clones, and enzalutamide significantly decreased viability in the 
FBS + DHT + MDV condition compared to FBS + DHT alone. However, viability in FBS + DHT + 
MDV condition was still higher than FBS + MDV, and was at a similar level to the FBS + 
DMSO condition in both clones. It was not clear why the effects of MDV when administered 
with 1 nM DHT differed between clones. 
 
3.4 | Murine Myc-CaP Bo prostate cancer cells respond to androgen deprivation 
It was also established that the 5GSH-6943#5 clone of the murine prostate cancer cell line 
MyC-CaP Bo responded to androgen deprivation. Initial experiments revealed only a small 
response to CSS and enzalutamide compared to FBS alone (Figure 10A). Whilst a relatively 
small response to enzalutamide concorded with previous experiments in this lab, a much 
larger effect of CSS was expected. Using different stocks of FBS and CSS did not much 
change the size of this effect, even after thawing a new frozen vial of 5GSH-6943#5 cells 
(data not shown). In addition, 1 nM DHT had a negative effect on the growth of cancer cells, 
as measured by both MTT assay and confluence (representative images shown in Figure 
10B). Further testing using different doses of DHT revealed that this effect was not due to 
the incorrect dose of DHT being given or the DHT stock being at the incorrect 
concentration: the effect was also seen at 10X lower dose using the same DHT stock as the 
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previous experiment, and at the same and 10X higher dose using new stock (Figure 10C). It 
appears that these cells underwent a phenotypic change in response to DHT, appearing 
smaller and more densely packed than cells treated with the other conditions (Figure 10B). 
This may have been due to alterations in AR signalling conferring a very different androgen 
sensitivity on cells: different 5GSH-6943#5 cells used later did not perform in this way. 
Closer examination of these cells revealed mycoplasma infection and cell line 
contamination, which may have been responsible for this unexpected behaviour. 
These cells were replaced with a new 5GSH-6943#5 stock, which underwent antibiotic 
selection with 1 mg/mL G418 to ensure the appropriate cells were being used. Multiple 
different FBS stocks were tested against CSS and with MDV treatment to determine the 
androgen sensitivity of the cells and whether different serum stocks gave different 
Figure 9: Response of 5GSH-6943 cells to double administration of DHT and MDV. 5-day assay in 24-well plate, 
changing media at day 3. Viability measured by MTT assay, OD 540nm. Data mean of 3 replicates from 3 repeat 
experiments, result from single experiment for a given condition represented by a single point, each repeat 
experiment represented by a different colour. Bars mean of three repeats values +/- S.E.M. Data normalised to 
mean FBS + DMSO value (normalised to 1). P < 0.05, comparison to FBS + DHT + MDV condition (2-way ANOVA, 




responses: as shown in Figure 10D, growth rate was slightly higher in the FBS stock of the 
lab of Professor Jeffrey Pollard than FBS used for other experiments in this project stored at 
-20oC or -80oC. Enzalutamide treatment reduced viability to a similar level in all FBS stocks: 
by 23% and 21% in the -20oC and -80oC FBS respectively, and by 37% in the FBS of the 
neighbouring lab. Faster growth in the Pollard lab FBS was thus androgen dependent, likely 
due to increased concentration of androgen. A stronger ADT response was seen in charcoal-
stripped serum reducing viability by 60%, 61% and 67% compared to the -20oC, -80oC and 
Pollard lab sera respectively. Whilst the greatest effect size was seen using FBS from the 
Pollard lab, a lack of availability of this serum meant that instead the FBS kept at -80oC was 
used for subsequent experiments in 5GSH-6943#5 cells. The new 5GSH-6943#5 cells also 
responded positively to androgen replacement by 1nM DHT in the CSS condition, although 
viability was still substantially lower than in FBS alone.  
 
Figure 10: Response of 5GSH-6943#5 murine prostate cancer cells to androgen deprivation. (A) 5-day MTT 
assay single experiment in 12 well plate (5000 cells/ well seeded) of 5GSH-6943#5 cells under various conditions 
of androgen supplementation and deprivation (OD 540nm, normalised to FBS value). (B) Representative images 
from 96-well 5GSH-6943#5 experiment, using same batch of cells as in (A) and (C). 10X objective, taken at day 5 
with IncuCyte Zoom® (C) 96-well MTT experiment testing dose of DHT on 5GSH-6943#5 cells. Seeded 1000 cells/ 
well, OD 540 nm (normalised to FBS) +/- S.E.M (3 replicates each condition). (D) 5-day experiment, 500 cells/ 
well seeded in 24-well plate. MTT assay of growth response to androgen deprivation and different batches FBS. 
OD 540nm normalised to FBS -20oC +/- S.E.M. (3 replicates) 
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3.5 | Optimisation of cell density 
Miniaturisation of this low-throughput assay onto a 96 well plate required the optimal cell 
seeding density per well to be elucidated. To find this, a twofold serial dilution was 
performed to achieve a range of cell densities on a 96 well plate, and confluence was 
measured at sequential time points for five days using the IncuCyte Zoom® microscope 
(Figure 11). The appropriate number of cells to seed for a five-day assay could be 
determined by identification of trace approaching reasonably high levels of confluence by 5 
days whilst remaining in logarithmic growth phase and growth not slowing due to contact 
inhibition (shown by a decrease in the slope of the curve, for example in Figure 11E). Plates 
were not kept incubated in this experiment for more than 5 days due to nutrient depletion 
and waste product generation in the media, thus extrapolation of the curve a further 24 or 
48 hours is required, as cells were seeded one or two days before treatment. Furthermore, 
as subsequent assays would utilise a 10% FBS + DHT condition, cell densities selected would 
need to allow room to account for the higher growth rate with additional androgen.  
For the CWR22PC_GB_02, 06 and 07 cell lines, confluence remained low even after 5 days 
(Figure 11A, B, C). For these cell lines, a density of 8000 cells was chosen: this was adjusted 
to 7000 cells/well for the faster growing CWR22PC_GB_22 clone (Figure 11D). Whilst this 
meant that confluence was still quite low at the end of the experiment, seeding densities of 
10000 and above had too high a starting confluence, and may have been affected by too 
much cell-cell contact at early stages of the experiment. Furthermore, the ratio of increase 
in confluence over the 5-day period was found to be the same or even larger at 8000 cells 
seeded compared to 12000 (Table 1). Low final confluence values in DMEM + 10% FBS for 
CWR22PC_GB_02,06 and 07 also left room for confluence to be considerably increased by 
supplementation with 1 nM DHT without cells becoming overconfluent. The 5GSH cells 
grew much faster and a lower cell density was required: due to an overlap in traces at the 
between the 1000 and 750 densities (Figure 11E), the experiment was repeated with cell 
densities of 1000, 750 and 500 (Figure. 11F), from which an appropriate starting density of 







Figure 11. 96 well plate experiments to elucidate optimal seeding density in various cell types. Achieved 
by twofold serial dilution of cells seeded across the plate. Four 10X images taken per well using an IncuCyte 
Zoom® microscope. (A – D) CWR22PC_GB_02,06,07,22 clones, images taken every 3 hours. (E, F) 5GSH-
6943#5 cells, images taken every hour Cells imaged from immediately after seeding with exception of (F), 
where imaged 24 hours later. Overlapping data in (E) necessitated a repeat of the experiment for the 
lowest cell densities (F). Depicted mean of three replicates (each the mean confluence of four images per 





5GSH-6943#5 5GSH-6943#5 repeat 
Table 1. Ratio of change in confluence (mean of confluence from 3 replicate wells) over 5 days between 
beginning and end of seeding density experiment (first and last data points) between the 12000 and 8000 – 
cell seeding densities. 
CWR22PC_GB_02 CWR22PC_GB_06 CWR22PC_GB_07 CWR22PC_GB_22
12000 cells/ well 2.29 2.31 1.76 2.56
8000 cells/ well 2.25 3.22 1.88 3.02
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3.6 | Determination of optimal dose of enzalutamide for murine experiments 
For experiments using CWR22PC cells, a dose of 1µM enzalutamide was used for high 
throughput experiments: this had already been shown to produce a strong response in 24 
well plate experiments (Figure 7). For 5GSH-6943#5 cells, dose response experiments were 
carried out varying MDV dose by threefold serial dilution. From these data (Figure 12), 
there is little response to MDV below 0.3 µM MDV, where viability falls steeply, then 
steadily decreasing as MDV3100 concentration rose further. The IC50 for the dose response 
curve was calculated to be 5.9 µM, however, 1 µM was still chosen: it is more in line with 
other publications and considered more relevant to the treatment dose in vivo 15,45 and still 
fairly close to the IC50, considering dose was varied on a log scale. This data ideally would 
have been repeated to achieve a more reliable measure of IC50. Nevertheless, a dose of 1 
µM MDV in this experiment produces a decrease of around 30%, in line with other 
experiments using this cell line in this investigation (Figure 10D).  
3.7 | Optimisation of CellTiter-Blue incubation time 
To ascertain the amount of time needed to incubate cells for assays using CellTiter-Blue, 10 
µL CellTiter-Blue was added to each 100 µL well on day 5 of a 96-well plate androgen 
deprivation assay using CWR22PC_GB_02 and 22 cells. The plate was then incubated in the 
dark at 37oC and 5% CO2. Fluorescence was measured at 585nm after exciting at 550nm, at 
90 minutes, 180 minutes and 360 minutes after CellTiter-Blue addition. The plate was then 
stored in the dark overnight at room temperature, then read again 24 hours after CellTiter-
Blue addition. In both clones, there were slightly larger differences between conditions 
after 3 hours compared to 90 minutes; differences after 6 hours were either equal or 
slightly lower than at 3 hours (Figure 13). The 24-hour timepoint showed a reduction in the 
Figure 12. Determination of optimal dose of MDV 
for murine prostate cancer cell experiments. Dose 
response of 5GSH-6943#5 cells to enzalutamide 
(MDV3100) measured by MTT assay after 5 days. 
Seeding 1500 cells per well in 96 well plate, media 
replaced after 3 days. OD 540nm, data normalised 
to highest mean value (=100). Mean of three 
replicates +/- SEM. IC50=5.9x10-6 M.  R2 = 0.7823 
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difference between conditions due to the exhaustion of all CellTiter-Blue present in some 
wells (data not shown). Based on this data, an incubation time of three hours was chosen 
for subsequent conditioned media response and min-max experiments using CellTiter-Blue. 
3.8 | Response of CWR22PC cells to MSC-conditioned media.  
Five-day 96 well assays were performed using human bone marrow MSC (BM-MSC)-
conditioned media to investigate whether secreted factors from MSCs affect prostate 
cancer cell growth with and without androgen deprivation. Figure 14A shows the combined 
results of three replicate experiments using 1:2 diluted MSC-conditioned medium on 
CWR22PC_GB_22 cells for 5 days. Media was changed at day 3, using the same CM that had 
been used at day 0 (stored in the interim at 4oC). As conditioned media could only be 
prepared in FBS, CSS conditions contained 6.7% CSS and 3.3% FBS. Individual two-way 
ANOVA analyses of the effect of CM on total viability for each condition did not reveal a 
significant difference in any of the 4 conditions, however the increase in viability with 
conditioned media in FBS + 1 µM MDV trended towards significance (P=0.1045). The effect 
of conditioned medium was small, increasing viability by 36% in the FBS + MDV condition, 
and much smaller rises in FBS and CSS. The markedly higher effect in FBS + MDV than CSS, 
was likely due to the presence of FBS in the CSS condition: compared to the FBS condition, 
proliferation was impaired much less compared to FBS + MDV (by roughly 35% and 75% 
respectively). Notably, conditioned media had a negative effect on cell number in the CSS + 
1 nM DHT condition, despite viability in CSS + DHT being no higher than in FBS.  
Figure 13. Determination of optimal time of incubation for CellTiter-Blue assay. Cells seeded at 8000 
(CWR22PC_GB_02) or 7000 (CWR22PC_GB_22) cells per well and treated 2 days later; media then changed at 
day 3. 10 µL CellTiter-Blue added with automatic multichannel pipette directly to the treatment media at 5 
days. Fluorescence read with excitation at 550nm, emission at 585nm. Readings after 90 minutes, 180 minutes 
and 360 minutes at 37oC and 5% CO2. Mean fluorescence intensity (of 3 replicate wells)) +/- S.E.M. CSS and 
FBS + 1 µM MDV traces for CWR22PC_GB_22 clones overlaid upon eachother. 
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Due to constraints of time and the cells used it was not possible to complete three 
biological replicates for the other CWR22PC clones. However, preliminary experiments 
were performed using the CWR22PC_GB_02 and CWR22PC_GB_06 clones (Figure 14B, C). 
Neither clone responded as greatly to 1 µM enzalutamide as the CWR22PC_GB_22 cells, 
however, both clones showed a greater response to BM-MSC conditioned media: similarly, 
the positive effect was proportionally greatest in the FBS + MDV condition (72% and 96% in 
the GB_02 and GB_06 clones respectively). A two-way ANOVA between the three replicate 
wells, comparing normal media to CM for all conditions (using Sidak’s correction for 
multiple comparisons) showed a significant (P<0.05) increase in all conditions bar CSS+DHT 
in CWR22PC_GB_06 cells. In the CWR22PC_GB_02 clone, there was a significant increase in 
the CSS and FBS + MDV treatments, with a trend towards significance in the FBS condition. 
However, as this analysis was performed using data from only one experiment, it is not 
correct to say that a significance response to CM has been identified.  
Data was collected using both CellTiter-Blue and MTT assays in this experiment, and by 
confluence measurement with the IncuCyte Zoom®. MTT was the more sensitive assay, 
giving proportionally larger differences than CellTiter-Blue between conditions. The MTT 
data also concorded much more closely to the confluence values, suggesting that the MTT 
assay results were more representative of the actual total cell number (Figure 14D). Later 
min-max experiments, comparing alternate rows of control and treatment replicates over a 
whole plate, would confirm a smaller effect size when using CellTiter-Blue. 
 
3.9 | Determination of optimal assay protocol in CWR22PC cells 
It is preferable to avoid changing growth media during an in vitro assay if possible, as it may 
cause loss of cells, changing concentrations of compounds within the media and disruption 
of other conditions affecting growth, such as temperature and pH. This could be achieved 
by reducing the length of the assay or by conducting the assay for five days without media 
replacement. Use of the IncuCyte Zoom® to monitor confluence in cells undergoing 
androgen deprivation shows that the majority of the response of CWR22PC cells to 
enzalutamide occurs after day 3 (Figure 15). Confluence clearly starts levelling off between 
48 and 72 hours in both the 10% FBS + MDV and 10% CSS traces, after which it begins to fall 
in the enzalutamide (MDV)-treated condition and no longer increases in the CSS condition. 
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The downward drop at 72 hours (particularly in the 10% FBS + MDV trace) is likely due to 
mechanical loss of cells during media replacement. Confluence in the CSS trace is likely 
lower due to loss of cells during the media changing process, however the effect of CSS in 
Figure 14. CWR22PC cell growth is stimulated by bone marrow MSC – conditioned media. (A) 
Combined data from three 5-day 96-well experiments on CWR22PC_GB_22 cells (seeded 7000 
cells/well), read by MTT assay. Means of three technical replicates taken and normalised to mean FBS 
value (=1), then data from three biological replicates combined. Normalised OD 540nm +/- S.E.M. (B, 
C) Single experiments in CWR22PC_GB_02, and _06 clones: 5 day 96-well experiment, seeded 8000 
cells/well. Mean of 3 replicate wells MTT signal OD 540nm normalised to mean FBS value +/- S.E.M (D) 
Comparison of CellTiter-Blue and MTT assays, and confluence data obtained from IncuCyte Zoom® 
microscope, read from same 96 well plate for CM experiment on two CWR22PC clones. All three 
readings taken sequentially from the same plate. Data for MTT and CellTiter-Blue assays normalised to 




CWR22PC_GB_22 Combined Data 
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reducing cell proliferation can still be seen. These results suggested that a 3-day assay was 
not viable for this investigation, which was confirmed by later min-max assays. 
To investigate whether the media change at day 3 could be omitted, during experiments 
testing the response of CWR22PC clones to androgen deprivation and MSC conditioned 
media, assays were performed with and without this media change (Figure 16). When 
media was changed on day 3, the same conditioned media as used on day 0 was used, 
stored at 4oC in the interim. Omission of the media change did not reduce the ability of the 
assay to discern differences between these conditions for either the CWR22PC_GB_06 or 
GB_22 clones. In fact, a slightly greater CM effect in FBS + 1 µM MDV was seen when the 
media was not changed (Figure 16, Table 2). Also, monitoring of CWR22PC cells seeded at 
the same densities for five days without a media change did not show any indication of 
reduced growth rate due to nutrient starvation (Figure 11). Changing the media at day 3, if 
using the same CM at day 3 than at day 0, was thus unnecessary for this assay. It is possible, 
however, that a greater effect of conditioned media could be obtained if, when changing 
media at day 3, freshly obtained conditioned media is used. This was found to be the case 
in 5GSH-6943#5 cells, as described below (Figure 17). However, due to the constraints of 
the slow growth rate of the primary human BM-MSCs, this investigation could not be 
performed within the timeframe of this project.  
Figure 15. Most of response to androgen deprivation in CWR22PC cells occurs after day 3. 5 day 96-well plate 
experiment investigating effects of enzalutamide (MDV) and charcoal stripped serum (CSS) over time. Cells 
seeded at 8000 per well in DMEM + 10% FBS; media changed in FBS + MDV and CSS conditions after 4 hours 





3.10 | 5GSH-6943#5 cells to MSC conditioned media under androgen deprivation 
conditions 
5-day high throughput experiments were also performed to test the response of 5GSH-
6943#5 cells to CM of the C3H10T1/2 murine MSC line. Unlike the primary human MSCs, 
C3H10T1/2 cells were capable of growth in media containing charcoal-stripped serum, thus 
CSS conditions contained 100% CSS. This assay was performed both with and without a 
media change on the third day, using freshly obtained C3H10T1/2 CM (Figure 17). 
FBS / FBS+ MDV CM/NM (FBS + MDV)
CWR22PC_GB_06
Media Change Day 3 2.45 1.96
No Media Change 5.29 2.14
CWR22PC_GB_22
Media Change Day 3 2.83 1.26
No Media Change 3.95 1.33
Table 2.  Proportional differences between 
FBS and FBS + MDV and between FBS + 
MDV and FBS + MDV CM conditions in the 
assay shown in figure 16, with or without 
media replacement (using the same 
conditioned media as before stored at 4oC) 
at day 3 of the 5-day assay. 
Figure 16. Omission of media change at day 3 does not affect response to conditioned media. 96-well assay 5 
day in CWR22PC_GB_06 and CWR22PC_GB_22 clones showing total cell viability as measured by MTT assay in 
response to androgen deprivation (by CSS or MDV) and MSC conditioned media. Conditioned media contained 
10% FBS before conditioning with mesenchymal stem cells for 24 hours, then diluted 1:2 into normal media to 
give treatment condition. Therefore, to control, all CSS conditions contain 1/3 either standard DMEM + 10% 
FBS or MSC-conditioned DMEM +10% FBS. Mean OD 540nm of 3 replicate wells normalised to mean FBS value 
+/- S.E.M of 3 replicates.  
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Comparing 3 replicate wells of each condition in this single experiment, only in the CSS 
condition did MSC-conditioned medium cause a significant increase in total viability both 
with and without a media change (P= 0.0046 and 0.0347 respectively, 2-way ANOVA 
comparing CM to normal media for all conditions, with Sidak’s correction for multiple 
comparisons). The positive effect of CM in FBS + 1 µM MDV without a media change and 
the negative effect in the FBS condition when media was changed on day 3 were also 
significant by this analysis. However, as with the CWR22PC data, we cannot assert a 
significant effect of C3H10T1/2 CM on this cell line, as doing so would require analysis of at 
least three repeated experiments. From these data, it appears that MSC-conditioned media 
only has a particularly substantial positive effect on 5GSH-6943#5 cell growth at castrate 
levels of androgen (i.e. in CSS). However, there was an increase in the CSS + DHT condition 
which trended towards significance (P=0.0605) when media was changed at day 3, in 
contrast to the decrease in growth in CWR22PC cells (Figure 14). When new media was 
applied at day 3 there was a greater increase in cell growth in the CSS condition caused by 
conditioned media than when there was no media change, although the difference was 
fairly small (61% with fresh CM at day 3, compared to 47% with no media change). A 
greater reduction in growth in CSS compared to FBS was also seen when the media was 
changed at day 3.  
Data for the effect of conditioned media in the CSS and FBS conditions (without the day 3 
media change) in the assay in Figure 17 was combined with two min-max assays each 
comparing the two conditions, to allow for statistical analysis of response conditioned 
media in these conditions. A paired t-test demonstrates that there is a significant response 
Figure 17. 5GSH-6943#5 response to C3H10T1/2 conditioned medium. 5-day assay in 96 well plate, with/ 
without media change at day 3 using fresh C3H10T1/2-conditioned media. Total viability of well measured 
by MTT assay, OD 540nm mean of three replicates normalised to mean FBS value +/- S.E.M.  
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(P=0.041) to C3H10T1/2-cell conditioned media in the CSS condition in this cell line (Figure 
18A). There was no response to CM in the FBS condition (Figure 18B). 
 
3.11 | Assessment of suitability of the CWR22PC_GB_22 clone for high throughput drug 
screening 
Min-max signal variability assays comparing difference in cell growth between FBS and FBS 
+ MDV were undertaken for the CWR22PC_GB_22 clone to determine the signal-to-noise 
between control and treatment groups, in terms of the assay window and variance of 
replicates. CWR22PC cells were treated in alternating columns between the two conditions 
and read by either MTT or CellTiter-Blue assay at day 3 or day 5. Confluence was read using 
the IncuCyte Zoom® immediately before addition of the viability assay reagent. Media was 
not subsequently changed during the assay period, as per previous findings (Figure 16). 
Coefficient of variance and Z’ data is summarised in Table 3. Reading the plate at day 3 did 
not give a high enough effect size to be suitable for a drug screen by any modality: MTT 
experiments after 3 days in this clone gave Z’ values indicating a highly marginal assay (0.09 
and 0.15), whilst CellTiter-Blue and confluence readings gave negative Z’ values. This was 
likely mostly due to insufficient effect size at 3 days (compare Figures 19A, 19B).  At 5 days, 
the MTT assay gave Z’ values of 0.74 and 0.40; whilst CellTiter-Blue gave substantially lower 
Z’ scores of 0.22 and -0.48, indicating a marginal and an unusable assay respectively. The 
Figure 18: C3H10T1/2 – conditioned media stimulates 5GSH-6943#5 growth in the CSS condition. (A) 
Response in the CSS condition, MSCs cultured with CSS for CM production. (B) Response in the FBS condition, 
MSCs cultured with FBS from CM production. Data from 3 experiments (one experiment per line), 5-day assay 
in 96 well plate, no media change at day 3. Mean OD 540nm by MTT assay, normalised to mean CSS/ FBS value 
between 3 experiments. Paired t test, P<0.05. 
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difference in Z’ is due to a smaller difference between the means in the CellTiter-Blue assay 
(Figure 19): CV values were similar between the two assays. As in previous experiments 
(Figure 14), confluence data (Figure 19C) concorded much closer with the MTT than the 
CellTiter-Blue assay, suggesting MTT was more representative of total cell number.  
The Z’ values for confluence at day 5 varied widely, ranging from 0.59 to 0.07: at the higher 
end, confluence could thus provide an ideal assay for high throughput screening, although 
for each plate the Z’ for the MTT assay was greater. The effect size between the means of 
the two conditions of the MTT assay (3.59 and 3.51-fold) was larger than that between the 
confluence values (2.74 and 2.57-fold) read on the same plate. This may be due to 
enzalutamide inhibition of cell viability, increasing the likelihood of accidental detachment 
and loss of cells during changing media to add MTT. It is more likely, however, that 
confluence underestimates the difference between conditions: it is by its nature 
considerably less sensitive and accurate a measure of cell number than viability assays, and 
will detect dead or minimally viable cells, possibly causing it to overestimate cell growth in 
the enzalutamide condition. These experiments therefore demonstrate that the MTT assay 
is the most suitable measure of cell number for a drug screen based on this assay. 
Figure 19D shows data from Figures 19A-C transposed and displayed by rows across the 
plate, rather than by column. This reveals some drift effects in some plates, chiefly the 
CellTiter-Blue day 3 plate, which had 27% drift between the means of the top and bottom 
row. The day 3 MTT assay also had a drift of 19%, just below the significance threshold of 
20% 95. Such plate effects, caused by experimental errors, increase CV values and thus 
decrease the value of Z’. However, as these effects were not consistent or predominant 
across multiple experiments, they can be considered insignificant to the overall 
investigation 95.  
  
3.12 | Assessment of the suitability of 5GSH-6943#5 cells for high-throughput screening. 
Once it was established that 5GSH-6943#5 cells responded well to androgen deprivation in 
the CSS condition, min-max signal variability assays were performed to determine whether 
this cell line would be suitable for high throughput screening using the assay developed in 
this project. Assays were performed comparing cell viability in FBS (maximum) against the 
androgen deprivation conditions of either CSS or FBS + 1 µM MDV (minimum). Data from 
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these experiments is summarised in table 4 and Figure 20. All plates were read using the 
MTT assay: experiments using CellTiter-Blue were not carried out based on min-max data in 
human cells (Figure 19, Table 3). As in CWR22PC cells, Z’ values were highest at 5 days: at 3 
days Z’ values were all negative, indicative of an assay with very limited use in high-
throughput screening 94. Notably, there was little change in the effect size between day 3 
and day 5 when comparing FBS to either FBS + MDV (Figure 20A) or to CSS (Figure 20B), 
however, the coefficients of variance were much lower at day 5, indicating more 
reproducible results. When comparing FBS and FBS + MDV, the Z’ values were too low for 
high-throughput screening even at day 5. As the CV values at day 5 were low and indicative 
of good reproducibility between replicates, the lack of utility of this assay was mainly due to 
the small effect size between FBS and FBS + MDV (15-25%). The two Z’ values in this 
experiment differed greatly due to a smaller effect size in the second repeat, possibly due 
to a seeding error leading to confluence being high enough for cells to begin to undergo 
contact inhibition by day 5. CSS had a much larger (50-60%) effect on total cell viability 
compared to FBS: again, the coefficients of variance were at an acceptable level, yet Z’ 
values were only 0.16 and 0.24. Whilst these Z’ scores are fairly low and have less ability to 
rank ‘hits’, they still have use for binary hit identification, and thus this assay would still be 
suitable as a base for a smaller-scale screen with an approved drug library. It should also be 
noted that we identified another stock of FBS which conferred a greater difference on 
5GSH-6943#5 cell growth compared to androgen deprivation conditions than the FBS used 
in these experiments (Figure 10D): use of this or another serum would increase the effect 
of ADT, and would likely increase these Z’ values.    
Table 3: Summary of Coefficient of Variance (CV) and Z’ data from min-max assays between FBS and FBS + MDV 
conditions in the CWR22PC_GB_22 cell line clone.  
Cell line Exp. CV FBS
CV FBS 
+ MDV Z' CV FBS
CV FBS 
+ MDV Z' CV FBS
CV FBS 
+ MDV Z' CV FBS
CV FBS 
+ MDV Z'
CWR22PC_GB_22 1 7.74 13.93 0.09 3.41 10.26 0.74 10.02 13.44 -1.33 3.40 10.05 0.22
2 6.25 12.10 0.15 9.62 16.10 0.40 5.21 6.95 -0.69 11.91 18.71 -0.48
CWR22PC_GB_06 1 21.92 26.52 -4.27 11.77 21.83 0.07
Cell line Exp. CV FBS
CV FBS 
+ MDV Z' CV FBS
CV FBS 
+ MDV Z' CV FBS
CV FBS 
+ MDV Z' CV FBS
CV FBS 
+ MDV Z'
CWR22PC_GB_22 1 5.50 8.78 0.59 8.89 21.82 0.30
2 8.11 14.43 -0.72 10.79 13.15 0.22 14.32 16.26 -1.27 10.42 17.19 0.07
CWR22PC_GB_06 1 17.33 23.25 -2.83 15.55 13.73 -0.89
Confluence of MTT plate Confluence of CellTiter-Blue plate
Day 3 Day 5 Day 3 Day 5
CellTiter-BlueMTT Assay








Figure 19: Results of Min-Max assay in CWR22PC_GB_22 cells. Scatter plot of single representative min-max 
assay between FBS and FBS + 1µM MDV conditions in the CWR22PC_GB_22 clone, seeded at 7000 cells/well 2 
days before treatment. Data taken from min-max experiment 1 (Table 3). Measured by MTT assay and by 
CellTiter-Blue assay at 3 days (A) and 5 days (B).  (C) Confluence values of day 5 min-max assay plates assayed 
in (B) as measured with an IncuCyte
 
Zoom® microscope, 4 images per well at 10X objective. Data for (A-C) 
organised per 6-well column, alternating between FBS (green) and FBS + 1µM MDV conditions. (D) Data from 
(A-C) transposed and presented by rows across the plate, 10 replicates per row. Wells in FBS displayed in 
green, in FBS + 1 µM MDV in orange. 
Table 4: Summary of Z’ and coefficient of variance (CV) values for min-max assays comparing FBS to either 
charcoal stripped serum (CSS) or administration 1 µM enzalutamide (MDV), in 5GSH-6943#5 cells (2 
experiments, 500 cells/well seeded in 96 well plates, MTT assay at either 3 or 5 days).  Each comparison a 
different plate. 
Cell line Exp. CV FBS
CV FBS 
+ MDV Z' CV FBS CV CSS Z' CV FBS
CV FBS 
+ MDV Z' CV FBS CV CSS Z'
5GSH-6943#5 1 8.65 12.26 -1.59 14.82 15.01 -0.43 3.83 5.46 0.07 10.92 8.78 0.16
2 13.08 17.78 -2.64 10.29 17.88 -0.36 4.86 8.32 -1.63 7.95 8.65 0.24
Day 3 Day 5
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Based on the response of the 5GSH-6943#5 cells to C3H10T1/2 cell conditioned media, min-
max assays were also performed to establish whether the effect size of total cell viability 
between unconditioned and MSC-conditioned was sufficient for high-throughput screening. 
Assays at day 3 were not performed, due previous experiments showing high CV and low Z’ 
values (Table 4). Assays compared FBS to FBS-CM and CSS to CSS-CM, with the data 
summarised in Table 5 and Figure 21. Confirming previous data (Figure 18), there was a 
sizable positive response to conditioned media in the CSS condition, but in the FBS 
condition CM had no effect. Despite this, high coefficients of variance and a relatively low 
effect size produced a negative Z’ value between CSS and CSS-CM, indicating that this assay 
is not suitable for a HTS in its current form. CV values were markedly higher than those at 
day 5 in this cell line for androgen deprivation assays: the reasons for this are not clear. The 
proportional response to conditioned media was shown to be larger by measurement of 
confluence (Figure 21B) than by MTT assay (Figure 21A), in contrast to CWR22PC cells 
(Figure 19), however confluence readings also had much greater coefficients of variance, 
and so yielded even less suitable Z’ values. The high CV values may be due to the 
characteristics of growth of 5GSH-6943#5 cells in the well: cells are seeded at very low 
density and grow into small clustered colonies rather than uniformly across the plate, or to 
collect at the edge of the well. These effects may confound the accurate association of the 
confluency metric with cell number and thus cell growth. 
Z’ values differed substantially between repeats using the same assay. This was likely due to 
inconsistency in the concentration of growth stimulating factors in the conditioned media, 
due to variation in the number of C3H10T1/2 cells present during CM production. Drift 
effects of 21% (in the MTT assay data) across the columns of the plate were also seen in the 
Figure 20: 5GSH-6943#5 androgen deprivation min-max experiments. Total viability of 5GSH-6943#5 cells at 
day 3 and day 5 of min/max assay, as measured by MTT assay. One representative experiment displayed 
(experiment 1 on Table 4). OD 540nm normalised to mean FBS value. 500 cells/ well seeded on 96 well plates. 
(A) Viability at day 3 and day 5 for min-max assays between FBS and FBS + 1µM MDV. (B) Viability at day 3 and 
day 5 for min-max assay between FBS and CSS. 
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first experiment comparing CSS and CSS-CM, both (Figure 21A, left panel; Figure 21B, left 























5GSH-6943#5 1 1.57 14.58 8.36 -0.46 1.8 20.72 16.58 -0.90 0.96 7.77 8.61 -13.98 1.03 15.22 17.21 -31.20
2 1.54 29.11 27.70 -2.95 0.97 7.98 11.03 -19.97 0.85 16.48 29.76 -7.50
3 1.26 12.15 18.02 -2.84 1.59 36.53 25.84 -2.91
CSS / CSS-CM
ConfluenceMTT Assay
FBS / FBS - CM
MTT Assay Confluence
Table 5: Summary of min-max assay Z’, coefficient of variance (CV) and fold change (between normal and 
conditioned media) values for 5GSH-6943 cells, comparing control and C3H10T1/2 – cell conditioned 
medium with either 10% standard FBS or charcoal-stripped FBS (CSS). Assays performed over 5 days in a 96 
well plate, data read by MTT (OD 540nm) or confluence.  
Figure 21: 5GSH-6943#5 conditioned media min-max experiments. Data for one representative 
experiment shown (experiment 1 on Table 5 for both conditions). (A) Total viability of 5GSH-6943#5 cells 
at day 5 of assay, as measured by MTT assay. OD 540nm normalised to mean CSS or FBS value. Means of 6 
replicates in column, +/- S.E.M. (B) Confluence data, measured by IncuCyte
 
Zoom® microscope, 4 






Chapter 4 | Discussion 
 
In this project, five clones of the androgen-sensitive human prostate cancer cell line 
CWR22PC were characterised for their response to androgen deprivation. A 96-well plate 
cell growth assay was then designed and optimised to test the response (by total cell 
viability) of some CWR22PC clones and murine 5GSH-6943#5 prostate cancer cells to MSC-
conditioned media. Initial validation experiments were then performed on tested cell lines 
to assess the potential for use of the assay in a high-throughput screen. However, the 
ability of the assay to separate the two controls, as indicated by Z’, was not indicative of an 
assay suitable for drug screening, due to an insufficient effect size of MSC-conditioned 
medium on prostate cancer cell growth. 
Drug discovery through high throughput screening is an expensive process, and early 
go/no-go decisions are made based on primary screens using assays such as the subject of 
this project 101. A screen is only as good as the assay on which it is based, and thus it is 
crucial that this assay sufficiently recapitulates the in vivo pathophysiological environment. 
At present, however, there are few drug discovery studies incorporating stromal cells, 
despite their relevance to anticancer therapy: in prostate cancer, multiple studies have 
indicated that MSCs stimulate tumour growth and resistance to androgen deprivation 
therapy 65,66,75. However, such studies have not yet been performed using the CWR22PC 
prostate cancer cell line. The assay designed in this project is thus important both to 
characterise the effect of MSCs on CWR22PC cells during androgen deprivation and to 
provide a drug screening assay platform more relevant to the in vivo environment, to better 
identify potential effective treatments for CRPC. 
 
4.1 | Implications and limitations of low throughput androgen deprivation assays 
Initial experiments showed a strong response to androgen deprivation in all CWR22PC 
clones (Figure 7), whilst all bar the CWR22PC_GB_22 clone responded positively to 
additional DHT (Figure 8). However, the size of the response differed considerably between 
different clones, demonstrating heterogeneity in the CWR22PC cell line. Within tumours, 
clonal selection gives rise to heterogenous phenotypes 102: progression to CRPC will thus 
occur in only a subpopulation of tumour cells in vivo, or by different mechanisms in 
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different subpopulations. Notably, DHT produced a several-fold increase in viability in CSS 
in all clones, but this was only statistically significant for CWR22PC_GB_25. This is likely due 
to high variation in the raw optical density values (measuring the absorbance of the purple 
MTT product formazan) between the three experiments performed for each condition, 
particularly in CSS + DHT, giving large differences in the size of the response. This may be 
due to inconsistency in the number of cells seeded between repeat experiments: as growth 
was greatly increased by 1nM DHT compared to CSS alone, differences of a few hundred or 
thousand initial cells between experiments would be amplified to large differences in the 
effect size of DHT between these repeats. Additional repeats of this experiment would 
possibly reveal statistical significance of these results, otherwise an alternative approach, 
for example using a different method of cell counting or to ensure more equal cell seeding 
between different experiments, may have yielded more consistent results.  
Some clones also gave negative OD readings once DMSO background was subtracted, 
despite the presence of cells upon microscopic inspection. This may be due to insufficient 
sensitivity of the MTT assay in detecting low cell numbers. In addition, washing cells with 
PBS, adding DMSO to solubilise formazan and transferring formazan solution to a 96 well 
plate after MTT incubation may have introduced errors reducing the OD signal below 
background controls, and may have increased the variation between replicate wells. 
Optimising seeding density, MTT incubation time and the concentration of MTT added may 
improve the sensitivity of the assay.  
 
4.2 | Use of charcoal-stripped serum as a means of androgen deprivation 
CSS produced a stronger negative effect on growth compared to FBS than enzalutamide 
(MDV) in all CWR22PC clones, whilst in three of the clones FBS + DHT gave a higher signal 
than CSS + DHT. In addition to androgens, other steroid hormones, thyroid hormones and 
even some peptide hormones (such as alkaline phosphatase, lactate dehydrogenase and 
aspartate aminotransferase)., as well as glucose, vitamins such as folic acid and vitamin 
B12, and electrolytes such as magnesium, phosphorus, calcium and potassium have been 
shown to be reduced in charcoal stripping of FBS 103.  The use of CSS as a model of androgen 
deprivation is therefore not entirely comparable to growth in FBS or as relevant to the 
environment in vivo during ADT, as some of the reduced effect on growth compared to FBS 
may be due to the depletion of these other factors. Notably, however, this effect was not 
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seen in all clones. CSS can instead be compared to CSS + DHT, although a 1nM dose of DHT 
produced a much higher response than FBS alone in these experiments, and large 
differences were found between the CSS + DHT + MDV and FBS + MDV conditions in three 
of the clones (Figure 9). Inclusion of an FBS + DHT condition may provide further insight into 
the DHT response of prostate cancer cells, and into differences between FBS and CSS 
through comparison with CSS + DHT. 
 
4.3 | Androgen responsiveness in the 5GSH-6943#5 cell line 
Experiments using the murine prostate cancer cell line 5GSH-6943#5 required significant 
troubleshooting due to the lack of response to androgen deprivation of cells initially used, 
to ascertain whether the unexpected results were due to a fault with reagents and to 
investigate the unexpected response to DHT (Figure 10A). When a different batch of 5GSH-
6943#5 cells was used, this cell line was found to respond to androgen deprivation and 
additional DHT as expected, but showed a smaller response to ADT than CWR22PC cells 
(Figure 10D). Notably the Myc-CaP cell line (from 5GSH-6943#5 cells are derived) possesses 
greatly elevated AR expression 86 which may explain the reduced castration sensitivity of 
5GSH-6943#5 cells in comparison to CWR22PC 16. However, Watson et al reported a 6.2-
fold higher colony formation in FBS compared to CSS in the Myc-CaP cell line from which 
5GSH-6943#5 is derived: the lower CSS response in 5GSH-6943#5 cells indicated in our 
experiments may be due to clonal heterogeneity in the Myc-CaP cell line. Secondly, CSS had 
a much larger effect than 1 µM enzalutamide: a possible explanation for this is difference 
between the AR in human and murine cell lines reducing the ability of enzalutamide to 
inhibit the receptor. Whilst the ligand-binding and DNA-binding domains of human and 
murine AR are identical, there is only 76% similarity in the N-terminal regulatory domain 104. 
AR is amplified in this cell line (Watson), possibly reducing the effectiveness of 
enzalutamide inhibition. Furthermore, the removal of non-androgenic compounds during 
charcoal treatment of serum may comprise a large amount of this difference: notably, CSS + 
1nM DHT gave a considerably lower signal than FBS alone. However, other studies have 
shown found that 1nM of the synthetic androgen R1881 in CSS completely rescued Myc-




4.4 | Collection of confluence data over time using the IncuCyte Zoom® 
Experiments to find optimum seeding density for 96-well plate experiments were 
conducted over 5 days to avoid excessive nutrient depletion, thus extrapolation for an 
additional day was required to estimate the optimum cell density. Accurate estimation was 
difficult in 5GSH-6943#5 cells due to their high growth rate, leading to initial experiments 
using excessive seeding densities and requiring assaying on day four to avoid 
overconfluence. Low initial seeding density increased the proportional effect of 
approximations inherent in the (automated) cell counting, which were then amplified by 
high growth rate to give a high level of variation in final cell number between repeat 
experiments. Performing cell density experiments over six rather than five days, changing 
media 24 hours after seeding, as in other experiments, may have improved estimation of 
the correct cell density.  
In contrast to 5GSH-6943#5 cells, CWR22PC cells grew very slowly, such that, except for the 
CWR22PC_GB_22 clone (Figure 11D), the confluence traces do not appear to show cells 
growing in the logarithmic phase. This complicated estimation of the optimal seeding 
density for these clones. Also, the CWR22PC_GB_02 and 06 traces (Figures 11A, B) show 
fluctuations in recorded confluence, likely caused by opening and closing of the drawer of 
the IncuCyte Zoom® to add and remove plates, leading to shifts in the camera position 
between readings. In a few cases, these shifts could cause the microscope to take images 
including the edge of the well or beyond introducing considerable error. Use of ImageLock 
plates, which possess a marker tracked by the IncuCyte Zoom® ensuring image capture of 
the same well area each time, would have prevented these errors. 
 
4.5 | The effect size of MSC-conditioned media was insufficient for HTS and requires 
further optimisation 
Experiments using MSC-conditioned media in human cells produced only a modest effect. 
Whilst CWR22PC_GB_22 responded positively to conditioned media, the effect size was 
small and not statistically significant (Figure 14A). Although cell line availability issues 
meant that min-max experiments assessing the effect of CM in CWR22PC cells were not 
performed, Z’ values obtained using the 5GSH-6943#5 cell line, which had a greater 
response to CM, suggest that the effect would likely not be large enough to produce a 
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sufficient Z’ value. Administration of fresh conditioned media after 3 days would likely 
increase effect size in the cell line, as it did (albeit modestly) in 5GSH-6943#5 cells (Figure 
17). Reuse of CM used on day 0 at day 3 had no additional effect compared to not changing 
media (Figure 16), indicating that the factor(s) responsible for stimulating growth is or are 
inactivated after 72 hours at 4oC. For all experiments conditioned media was diluted 1:2 
into regular media to mitigate depletion of growth factors and nutrients by the MSCs. A 
higher proportion of conditioned media may have a greater effect on growth, although the 
greater depletion of nutrients and growth factors may lead to the opposite effect. This may 
be optimised by investigation of different dilution ratios. 
In preliminary experiments the CWR22PC_GB_02 and 06 clones had a stronger response to 
MSC-conditioned medium than CWR22PC_GB_22 cells (Figure 14A, B, C). These clones, 
CWR22PC_GB_06 in particular, may therefore be better candidates for high throughput 
screening, though both grew at a lower rate than CWR22_GB_22. One-way analysis of 
variance (ANOVA) on a single experiment for each clone showed a significant response to 
conditioned media for both clones, however as these results are only from a single 
experiment this analysis is of limited validity, as asserting statistical significance requires at 
least three biological replicates. Repeat experiments could not be performed in these 
clones due to mycoplasma infection of primary BM-MSCs. As they would not tolerate 
cryopreservation, the cells could not be replaced. In addition, both CWR22PC cells and 
primary BM-MSCs grew very slowly, making it challenging to co-ordinate cell seeding and 
collection of conditioned media to perform multiple experiments efficiently.  
The response to conditioned media was greatest in the FBS + 1µM enzalutamide condition 
for all CWR22PC clones tested: this is consistent with the in vitro results of Cheng et al. 
(2016) showing that MSC conditioned media completely rescued the growth of LNCaP cells 
grown in CSS and did not affect the growth of cells grown in the presence of androgen 75. 
However, the CM response in our experiments was not nearly as great as Cheng et al: this 
may reflect differences between the CWR22PC and LNCaP cell lines. However, in our 
experiments the FBS + MDV - CM condition used conditioned media containing FBS: Cheng 
et al. found that the effect of conditioned media depended on MSCs also being deprived of 
androgen 75. Future experiments could include enzalutamide in production of CM, or use 
CSS-CM added to FBS, to investigate whether depriving MSCs of androgen increases their 
effect on CWR22PC cells. This would also be more representative of in vivo 
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pathophysiology, where both tumour and stromal cells undergo androgen deprivation. 
However, in this project the primary MSCs used did not survive after conditioning with 
media containing CSS, and thus FBS-CM was used for all conditions due to scarcity of MSCs. 
The serum used in the CSS condition is thus 1/3 FBS, and thus is not very representative of 
ADT in vivo. This presence of FBS in the CSS condition may limit the effect of CM, due to 
inhibition of MSC TGFβ production by androgen and by reducing the effect of ADT for MSC 
stimulation of castration resistance to rescue. However, CM did stimulate growth in the FBS 
condition in this cell line, particularly in CWR22PC_GB_06 cells, suggesting that the effects 
of MSCs on this cell line are unlikely to be solely due to stimulation of castration resistance 
and may involve multiple mechanisms. However, it is possible that MSC CM may increase 
response to the relatively low androgen concentration in FBS: supporting this, conditioned 
media in CSS + DHT, with higher levels of androgen, did not stimulate cell proliferation. 
The response to murine MSC-conditioned media in 5GSH-6943#5 cells was broadly in line 
with CWR22PC cells. The increase in cell proliferation was greatest in the CSS condition 
(Figure 17), supporting the hypothesis that MSCs stimulate castration-resistant tumour 
growth. Unlike the primary human MSCs, the C3H10T1/2 MSCs used tolerated culture in 
CSS-containing media, allowing use of CSS-CM. In this sense results in this cell line are more 
representative of the in vivo condition than the CWR22PC experiments. C3H10T1/2 CM had 
a greater effect in the CSS condition than in FBS + MDV (which used FBS-CM), which may be 
due to ADT stimulating the effect of MSCs on castration-resistant growth. However, this 
may instead be due to the limited effect of 1 µM enzalutamide on 5GSH-6943#5 cells: if CM 
stimulates castration-resistant growth, its effect may be smaller if the growth inhibition of 
androgen deprivation is relatively slight. Repeating this experiment with higher doses of 
enzalutamide would help to ascertain if this is the case, but 1 µM is considered the clinically 
relevant dose of enzalutamide in vivo 15,45. One could also further investigate the effect of 
androgen on CM effect by including enzalutamide in conditioned media for the FBS + MDV 
– CM condition, or by adding FBS-CM to the CSS condition and vice versa (although this 
would not replicate in vivo pathophysiology). 
An inherent limitation of assays using conditioned media is reproducibility: it is difficult to 
estimate the number of MSCs present in the flask when media is changed and to keep this 
the same between experiments. Additional limitations in this project exacerbated this 
issue: CWR22PC cells required seeding a day before changing of MSC media, necessitating 
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anticipation of when MSCs would at a suitable confluence. By contrast, C3H10T1/2 cells 
grew very quickly, thus media was changed when confluence was fairly low, requiring 
estimation of confluence 24 hours later. Care was needed to assure a maximal number of 
cells to secrete castration resistance-stimulating factors, without cells becoming over-
confluent: C3H10T1/2 cells are highly sensitive to contact inhibition 87. These effects led to 
a large degree of variation between repeat experiments, reducing the reliability of Z’ scores 
as a measure of assay quality, and would undermine drug screening if repeated over 
multiple cell passages. 
 
4.6 | Viability assays 
Experiments using conditioned media utilised both CellTiter-Blue and MTT assays to 
measure total cell viability per well, to assess cellular proliferation. CellTiter-Blue has shown 
to be more sensitive to small changes and lower cell numbers than MTT 105, and is less 
prone to error 97, and thus would be expected to be the preferable assay. In our 
experiments, however, CellTiter-Blue showed much smaller differences between conditions 
than MTT (Figure 14D), thus giving substantially lower Z’ values (Table 3). Additionally, 
despite CellTiter-Blue being read directly from the plate without having to wash wells and 
solubilise with DMSO, which one would expect to reduce error, coefficient of variance (CV) 
between replicates was no lower than with the MTT assay.   
The reasons for the lower sensitivity of CellTiter-Blue in our investigations was not clear. It 
is possible that the three-hour incubation period with the assay reagent was too long, 
(something not revealed by a single optimisation experiment), or that cell number may 
have been too high for the assay to function effectively. If so, high rates of reduction by 
highly viable cells of high numbers of cells may have caused further reduction of the 
fluorescent product resorufin to the nonfluorescent hydroresorufin 93, reducing the signal in 
the well, whereas this will not occur as much in lower viability wells. This would lead to 
underestimation of cell number in high viability wells and a reduction in the apparent effect 
size. Further optimisation experiments, for example changing the concentration and 
incubation time of CellTiter-Blue, or applying it to a serial dilution of cells to determine the 
linear dynamic range, may have revealed these reasons and improved sensitivity. 
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Quantification of confluence is highly flawed as a measure of cell number. The density at 
which cells clustered together varies considerably and tended to increase with increasing 
confluence (Figure 10B). This would likely have caused underestimation of cell number at 
high confluence and overestimation at lower densities. The software used may also include 
as confluence spaces between cells that are close together but not in contact and dead or 
minimally viable cells that are not counted by viability assays, in addition to inorganic 
contaminants (such as fibres) background signal, particularly in cell lines which contrast 
poorly with the well surface. Accurate measurement of confluence also depends on cells 
being evenly spaced, yet cells tended to collect at the edge of wells outside the field of the 
micrograph, whilst 5GSH-6943#5 cells tended to grow into tight clusters. 
In 24 well plate experiments, MTT solution was added directly to the culture medium 
already present in the well, as per the existing lab protocol. Lower pH in wells with higher 
cell density may have had confounding effects: at low PH values the absorbance peak of 
formazan is lower, broader and shifted to lower wavelengths 106. In addition, the different 
growth conditions the cells were cultured in could affect the metabolic rate, and thus the 
level of MTT reduction by each cell. As previously discussed, there was a substantial 
amount of variation between replicates, and negative OD values at low viabilities. Use of a 
different assay would remove the need for washing or addition of DMSO, possibly removing 
sources of error and improving the consistency results. A resazurin reduction assay would 
be an obvious option, yet in this project sensitivity CellTiter-Blue was found to be 
substantially less sensitive, (though it was not tested on 24 well plates at a lower seeding 
density). Other formazan assays to MTT, such as XTT, WST-1 and CCK-8 have a higher 
sensitivity and form soluble formazans 107, removing the need for solubilisation with DMSO. 
Otherwise, assays measuring ATP concentration, such as CellTiter-Glo (Promega) may be 
preferable: CellTiterGlo is read by luminescence and thus does not require additional steps 
after addition of the assay reagent, has been shown to have considerably greater sensitivity 
than tetrazolium based assays, and is faster and simpler to use 108.   
In contrast to low throughput experiments, MTT and CellTiter-Blue were added to 96-well 
plates by mixing in DMEM + 10% FBS and added after aspiration of the treatment media. 
This ensured an equal concentration of assay reagent between wells of the plate: if only 5 
or 10 µL per well of reagent is added directly, pipetting errors of only a fraction of a 
microlitre will cause large errors in the reading. In addition, pH and media constituents 
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were equal between wells using this method: these variables thus would not have 
confounding effects on the reduction rate. Incubating all cells in the same media over the 
reagent incubation period may help equalise the metabolic activity per cell between 
different groups, making the assay more representative of cell number per well, although 
cells may take longer to adjust to the change in condition than the brief incubation time. 
Conversely, changing the media to add the assay reagent may have caused loss of cells, 
which may be more likely in the ADT conditions which reduce cell viability, possibly leading 
to overestimation of the effect of androgen deprivation. 
 
4.7 | High throughput screening: further optimisation required 
Min-max assays using CWR22PC_GB_22 cells show low variance between replicates and a 
high Z’ between FBS and FBS + MDV conditions, indicating the design and execution of the 
assay is of acceptable quality (Figure 19, Table 3). However, a drug screen needs to include 
conditioned media to be informative, to identify compounds which inhibit MSC stimulation 
of castration-resistant growth. Considering the small effect size of MSC-CM in the 
CWR22PC_GB_22 clone (Figure 14A), it is unlikely that a min-max assay between normal 
and conditioned media in the FBS + MDV condition would yield a sufficient Z’ value. Min-
Max assays between FBS and an androgen deprivation condition still help validate the 
protocol used, ensure that there are no errors such as drift effects, and judge whether the 
size of the ADT response is sufficient for drugs inhibiting MSC effects to be useful. Such an 
assay could also be used for screening compounds that may affect androgen sensitivity.  
It is possible that further optimisation could increase the effect size of conditioned media 
and thus improve Z’ to a level where drug screening would be justified. This may involve 
changes to the protocol to obtain and use MSC-conditioned media, use of a different 
viability assay or use of different cell lines or clones. In this study, we showed that a media 
change at day 3 using fresh CM increased effect size in 5GSH-6943#5 cells (Figure 17), 
however the size of this increase was not enough to justify performing min-max 
experiments employing this media change, as doing so would be unlikely to raise Z’ 
sufficiently. Changing the media midway through an assay would likely cause cells to 
become stressed or lost, and may cause the concentration of compounds between wells to 
differ: this may increase the coefficient of variance and thus in fact reduce Z’. The process 
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of changing the media also disturbs the conditions of the assay, reducing control over the 
environment and increasing variation between different plates.  
The assay may also be improved by use of different cell lines which exhibit a stronger 
response to conditioned media. Cheng et al. (2016) show a strong response to MSC-CM in 
the LNCaP cell line 75, however LNCaPs are less androgen-sensitive than CWR22PC cells 31 
and therefore may be a less suitable cell line for investigation of response to androgen 
deprivation therapy. The relatively low response of 5GSH-6943#5 cells to ADT may have 
limited the effect of MSCs on proliferation if MSCs function to stimulate castration 
resistance: identification of a more androgen sensitive cell line may allow for an increased 
effect of MSC CM. Identification of an alternative drug to enzalutamide may also give a 
larger ADT effect: this could be investigated through a pilot screen using a small, focused 
library of antiandrogens to identify the drug with the largest effect on a given cell line. 
However, enzalutamide is currently the drug given to patients when other forms of ADT has 
failed 24, and is thus likely the most relevant drug to include in a screen looking to identify 
new agents which could further increase the period of remission with ADT. Adding 
replicates to an assay for screening would also increase the power of the assay, although 
this would reduce the assay throughput 95.  
There are flaws with the use of Z’ to judge suitability for high throughput screening. Z’ is a 
highly conservative measure of separation between positive and negative controls: at a Z’ 
of 0.5, indicative of an ‘ideal’ assay 94, a full twelve standard deviations separate the two 
means. When Z’=0, commonly considered a ‘useless’ assay, the two means still differ by six 
standard deviations, and consequently there is less than a 1 in 90,000 chance of a positive 
response being less than a randomly chosen negative control value 109. This would suggest 
that, particularly if the aim of a screen is merely to identify rather than rank hits, assays 
with Z’ values considerably lower than 0.5 may still be useful for drug screening. High 
throughput screening is an expensive process and thus decisions on assay suitability will 
depend on weighing cost against the probability of success: a smaller, more targeted drug 
library may be suitable for assays with a Z’ closer to zero. There are other problems with 
the use of Z’ for a measure of assay quality: it is most often reported without confidence 





4.8 | High throughput screening based on an optimised assay 
Translation of this assay into a high throughput screen would require additional validation 
than min-max plate uniformity assessment assays to ensure that the assay is reproducible. 
As detailed by Iversen et al., this would require testing 20-30 compounds in the assay over 
two runs, and the results compared to measure reproducibility and variation in the 
potencies of these compounds between runs. There must be sufficiently little within-run 
and between-run variability for screening to go ahead 95. Notably, automation of processes 
in a high throughput screen would likely decrease coefficient of variance and improve Z’ 
value.  
Once an appropriately optimised assay has been shown by assay validation to be 
reproducible and to possess a sufficient assay window for hit detection, a screen would 
likely test an approved drug library to repurpose existing drugs, or a small library of diverse 
chemical structures to develop novel drugs, at either a single concentration or across a 
small range of concentrations (for example, 1, 5 and 10 µM). Success of drug screening 
depends not just on the quality of the assay on which it is based but on the drug library 
used. Library quality depends on a both inclusion of many widely diverse compounds and a 
focus on those with drug-like properties which are likely to have some activity on the target 
molecule or cell phenotype and thus produce screening hits. Optimisation of a screen must 
balance maximising the probability of identification of hit compounds and the time and 
monetary costs of performing the screen, which will increase with the size of the library 96. 
Drugs detected as a ‘hit’ can then be studied further in more detailed dose-response 
experiments, using at least five different concentrations, to better characterise their effects 
on castration-resistant prostate cancer cell growth and calculate the EC50 for that 
compound. EC50 gives a measure of the potency of the compound, allowing the most 
promising hits to be identified. Hits with sufficient potency can then be further 
investigated, for example by studying their chemical structure to inform design of novel 
lead compounds by other more targeted drug discovery programs. Leads are unlikely to be 
identified directly from a screen, but usually require further assays on similar compounds to 
further optimise the candidate compound 96. Investigation of the mechanism of action of 
hit compounds in promoting castration may also be performed, for example by analysis of 
their chemical structure or by using comparative phenotypic screening techniques such as 




4.9 | Future directions 
The chance of lead compounds being developed from screening hits depends not only on 
the size and relevance of the drug library used, but also on an assay closely enough 
representing the in vivo environment and disease pathophysiology. Future experiments, 
therefore, should utilise direct coculture of MSCs and cancer cells. A direct coculture assay 
would include the effects of cell-cell contact between MSCs and cancer cells, and of 
crosstalk between the two cell types, as MSC phenotypes are affected by signalling from 
tumour cells 53,69. In such an assay MSCs and cancer cells would both be exposed to the 
same conditions: as shown by Cheng et al., the level of androgen deprivation appears to be 
of importance in the effect of MSCs 75. Such a study was beyond the scope of this project, 
however, as the IncuCyte Zoom® was unable to distinguish between MSCs and prostate 
cancer cells and thus proliferation of prostate cancer cells alone could not be quantified. 
This investigation would require fluorescent cell labelling of distinct cell types, to enable 
detection of changes in prostate cancer cell number alone. Such a study would also require 
optimisation of seeding of both MSCs and prostate cancer cells in the same well, and may 
make comparison with cancer cell growth in the absence of MSCs more difficult. Relevance 
to the environment in vivo also depends on how closely the cell lines used represent the 
phenotypes of prostate cancer cells and MSCs in the tumour. Whilst experiments in human 
cells utilised primary bone marrow MSCs, experiments in murine cells used the MSC cell 
line C3H10T1/2: whilst BM-MSCs are a heterogenous population, C3H10T1/2 cells are 
homogenous and this cannot replicate the variety of phenotypes found in vivo 90.  
The assay format could be further elaborated upon to increase relevance to disease 
pathophysiology. Coculture of MSCs and tumour cells still does not include the complex 
network of interactions and signalling between tumour cells and many types of stromal and 
immune cells forming the tumour niche 53. One could attempt to better represent the 
tumour microenvironment by designing a coculture assay using more than two cell 
populations, although this will increase the complexity of optimising the assay. Restriction 
of cell culture to a two-dimensional cell surface also limits relevance to disease 
pathophysiology, as a cell monolayer cannot replicate the structure and spatial organisation 
of the tumour microenvironment 110; in addition, drug kinetics may differ and 2D 
experiments give have effective doses which are not effective when scaled to patients 101. 
75 
 
Recent developments have been made in design of three-dimensional organoid tumour 
models using extracellular matrix (for example Matrigel) frameworks 110. These most 
commonly only include a single cell population; however, hybrid organoids have been 
constructed using multiple cell types. For example, to investigate liver metastasis, Skardal 
et al (2015) created organoids including both hepatoma and colon carcinoma cells using 
simulated microgravity bioreactors, allowing cells to recapitulate the three-dimensional 
organisation present in vivo. Cancer cells cultured in the organoid structures possessed a 
notably different phenotype indicative of epithelial-mesenchymal transition (EMT), more in 
line with the metastasis-associated cell phenotype in vivo 101. Organoid cancer models have 
also been used in a 384-well format for high throughput screening by Boehnke et al. (2016): 
assay validation gave low CV values and high Z’ values above 0.5 111. However, there may be 
added complexity in HTS with hybrid organoids in assessment of cell proliferation. The 
extracellular matrix (ECM) may also play a role in cell behaviour relevant to the 
pathophysiology of cancer: both two- and three-dimensional tissue matrix arrays can be 
used in high throughput screening to include cell-ECM interactions. These arrays were 
created by chemical treatment of harvested porcine tissue to remove cellular material, 
before lysophiling into nanoparticles that retained the structure and proteomic complexity 
of ECM in vivo 112. The 3D microarrays were compatible with metabolic assays, and may 
further improve the relevance of HTS and thus the likelihood of lead compounds being 
effective in vivo.  
 
4.10 | Conclusion 
This project has thus demonstrated a positive effect of mesenchymal stem cell conditioned 
media on the growth of both human and murine prostate cancer cells, particularly under 
the condition of androgen deprivation. This supports the hypothesis that MSCs of the 
tumour stroma support acquisition of resistance of the tumour to androgen deprivation 
therapy. However, assay validation experiments show that further optimisation is required 
for this assay to be used to screen a drug library for compounds that could inhibit this 
effect. Such compounds, if investigated further, could be developed into lead compounds 
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